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ABSTRACT
The ability of taxol to induce apoptosis was compared in phenotypically dissimilar
MCF-7 and MDA-MB-231 human breast adenocarcinoma cells. To assess this,
morphological examination, PARP cleavage, and TUNEL assay was employed.
Treatment of these cells with 100 nM taxolled to chromatin condensation, DNA
fragmentation, and apoptosis-associated morphological changes after 3-24 hours
exposure. Additionally, proteolytic cleavage of poly (ADP-ribose) polymerase was
detected in MCF-7 but not MDA-MB-231 cells. To further elucidate these findings, the
expression of certain apoptotic regulatory genes was also examined by western blot
analysis. In MCF-7 cells, levels ofBcl-2 and p53 increased after 24 hours and 72 hours,
respectively, whereas no significant change in levels of cytochrome c was found.
Conversely, in MDA-MB-231 cells, levels ofBcl-2 and p53 decreased after 72 hours,
whereas cytochrome c levels increased after 72 hours. These data suggest that 100 nM
taxol induces apoptosis in MCF-7 and MDA-MB-231 cells, probably via a p53-
dependent and independent pathway, respectively. Bcl-2 and cytochrome c, however, did
not play clear roles. Increased understanding oftaxol-induced apoptosis may lead to the
development of more effective taxol-based chemotherapy regimens and improved clinical
responses.
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CHAPTER 1: INTRODUCTION
1.1 Cancer
Cancer is a devastating disease, claiming the lives of thousands of people each
year. An estimated 139,900 new cases of cancer and 67,400 deaths from cancer will
occur in Canada in 2003 (National Cancer Institute of Canada, 2003). Furthermore, an
average of 2,690 Canadians will be diagnosed with cancer and 1,296 will die of cancer
every week. Cancer is also the leading cause of premature death in Canada, being
responsible for almost 31% of all potential years of life lost.
It has been recognized for many years that cancer is a genetic disease (MacDonald,
F., et aI., 1997; Nowell, P.C., 1976). Cancer arises from a single cell that has undergone a
mutation, which gives the cell some heritable form ofgrowth advantage. The initial
mutation will cause the cells to divide to produce a genetically homogenous population of
cells. Further mutations will in tum occur, enhancing the cell's growth potential. These
mutations give rise to subclones with different properties within the tumor. Consequently,
most tumors are heterogenous.
Cancer development exhibits a multistage nature (MacDonald, F., et aI., 1997;
Nowell, P.C., 1976). In 1949, Berenblum and Shubik concluded that carcinogenesis was
at least a two-stage process. In 1954, Armitage and Doll took this observation a step
further and concluded that carcinogenesis was at least a six or seven stage process.
Furthermore, in 1957, Foulds showed that tumor progression occurred in a stepwise
fashion. From these observations, it is clear that malignancy occurs via a multistage
progression, although each of the steps cannot always be defined in an individual tumor
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(Figure 1.1.). The initial step of the multistage progression to malignancy is thought to be
caused by some form ofgenotoxic agents such as radiation or a chemical carcinogen. The
cells at this stage are phenotypically normal, although they have altered deoxyribonucleic
acid (DNA). Further mutations lead to the emergence of clones with additional properties
associated with tumor cell progression. Finally, additional changes allow the outgrowth
of clones with metastatic potential. Animal models of carcinogenesis have enabled these
steps to be classified as initiation, promotion, malignant transformation and metastasis.
Figure 1.1. Multistage Progression to Malignancy
(MacDonald, F., et aI., 1997; Nowell, P.C., 1976)
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1.2 Breast Cancer
Breast cancer is the most frequently diagnosed cancer in Canadian women,
accounting for almost 1 in 3 cancer diagnoses (www.cancer.ca/ccs). The Canadian
Cancer Society estimates that in 2003, an estimated 21,200 women will be diagnosed
with breast cancer and 5,300 will die of the disease.
Despite these grim statistics, the etiology of breast cancer remains poorly
understood. It is known that a complex interplay between hereditary and environmental
factors initiate and/or promote the disease. Factors associated with an increase risk
include early age of menarche and late stage of menopause, nulliparity, late age offirst
time pregnancy, family history ofbreast cancer and having the mutated breast cancer
genes BRCA1 or BRCA 2 (Campbell, J.B., 2002; Arver, B., et aI., 2000; Carolin, K.A.,
et al., 2000; Hsieh, T., et al., 1999). The effects of diet, physical activity, obesity,
alcohol, hormone replacement therapy and smoking are under study.
1.3 Cancer Chemotherapy
There are a number of effective treatment modalities for cancer, including surgery,
radiation therapy and chemotherapy. Surgery is often the first step in cancer treatment
because it's used to both diagnose and treat cancer (Merrick, H.W., 1995; Skeel (a), R.T.,
1995). Surgery is often utilized to obtain representative tissue so that accurate diagnosis
can be made. Once a cancer diagnosis is confirmed, surgery is often chosen as the
treatment modality if the cancer is limited to one area and it's anticipated that all the
cancer cells can be removed without harming vital structures. Surgery is also used to
reduce the size of large tumors so that follow-up treatment by radiation therapy or
chemotherapy will be more effective. In addition to curing cancer, surgery is used as a
preventive measure by removing precancerous conditions. Furthermore, surgery may be
recommended as a palliative measure to help reduce pain and other symptoms.
Radiation therapy is also used for the treatment of local disease. It may be
employed when surgery cannot remove all the cancer or there is potential to compromise
normal structures and functions (Skeel (a), R.T., 1995). Radiation therapy can be used in
conjunction with other treatment options such as surgery. Doctors may use radiation
before surgery to shrink a tumor, thus making it easier to remove. In addition, radiation
therapy may be used after surgery to stop the growth of cancer cells that may remain.
Furthermore, radiation therapy may be recommended as a palliative measure to shrink
tumors and reduce pressure, pain, and other symptoms of cancer. Once cancer has
metastasized to other areas of the body, however, both radiation therapy and surgery are
ineffective. In such instances, chemotherapy is often chosen.
The primary role of chemotherapy is in the treatment of cancer that is no longer
confined to one area and has spread systemically (Cella, D.F., 1995; Skeel (a), R.T.,
1995). If possible, chemotherapy is used to cure the cancer. If a cure is not possible,
chemotherapy is used to control the disease, by shrinking the tumor mass or by reversing
or slowing the rate of progression, in order to extend the life of the patient. Sometimes
control is unlikely, particularly if the cancer is in an advanced stage. In this case,
chemotherapy is used as a palliative measure to relieve symptoms of cancer.
Furthermore, chemotherapy is used in conjunction with other treatment modalities. For
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instance, it may be used to shrink a tumor before surgery or radiation therapy.
Chemotherapy can also be employed to destroy any cancer cells that may be remaining
after surgery and/or radiation therapy. In some cases, chemotherapy can make other
treatment modalities such as radiation therapy more effective.
Chemotherapeutic agents comprise a wide variety of drugs. They are customarily
divided into several classes and within each class there are several types of agents.
Examples of the classes of chemotherapeutic agents include alkylating agents,
antimetabolites, antitumor antibiotics and plant-derived agents.
1.3.1 Alkylating Agents
The alkylating agents are a diverse group of polyfunctional compounds that have
the ability to substitute alkyl groups for hydrogen ions (Skeel (b), R.T., 1995; May, D.M.,
et aI., 1994). These compounds react with a number ofnucleophilic groups, such as
phosphate, amino, hydroxyl, sulfhydryl, carboxyl and imidazole groups. At neutral or
alkaline pH, alkylators ionize and generate positively charged ions that attach to
susceptible nuclear proteins, particularly the N-7 position ofguanine. This alkylation
reaction leads to abnormal base pairing, cross-linking ofDNA, interference with DNA
replication and ribonucleic acid (RNA) transcription. Consequently, these effects result in
interruption in cell's normal functions.
The alkylating agents are cell cycle phase-nonspecific in that they exert their
activity regardless of the specific phase of the cell cycle (Skeel (b), R.T., 1995; May,
D.M., et ai., 1994). Alkylating agents include nitrogen mustards, ethylenimine
derivatives, alkyl sulfonates, triazine, nitrosoureas and metal salts. They are important in
such cancers as acute and chronic leukemias, Hodgkin's disease, non-Hodgkin's
lymphoma, multiple myeloma, primary brain tumors, malignant melanoma and
carcinomas of the breast, ovaries, testes, lungs, bladder, cervix, head, and neck.
1.3.2 Antimetabolites
The antimetabolites are a group of low molecular weight compounds that interfere
with metabolic processes vital to the physiology and proliferation of cancer cells (Skeel
(c), R.T., et aI., 1995; DeLap, R.J., 1994). They exert these effects due to their structural
or functional similarity to naturally occurring metabolites involved in nucleic acid
synthesis. Almost all of the currently used antimetabolites inhibit the synthesis of purine
or pyrimidine nucleotides and/or directly inhibit the enzymes ofDNA replication. Many
antimetabolites also interfere with RNA and ribonucleotide synthesis, amino acid
metabolism and protein synthesis.
Because of their primary effect on DNA synthesis, antimetabolites are cell cycle
phase-specific (Skeel (c), R.T., 1995; DeLap, R.J., 1994). They include folic acid
analogs, pyrimidine analogs and purine analogs. Antimetabolites are used in the
treatment of various cancers including carcinomas of the breast, bladder and colon, acute
and chronic leukemias, and non-Hodgkin's lymphoma.
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1.3.3 Antitumor Antibiotics
The antitumor antibiotics constitute a heterogenous group of chemotherapeutic
agents that affect the function and synthesis ofnucleic acids through various mechanisms
including DNA strand scissions, topoisomerase II-dependent cleavage, DNA
intercalation, cross-linking ofDNA strands, and inhibition ofRNA synthesis (Skeel (d),
R.T., 1995; Kobayashi, K., et al., 1994).
The antitumor antibiotics include anthracyclines (doxorubicin, daunorubicin and
idarubicin), mitomycin C, bleomycin, dactinomycin and plicamycin (Skeel (d), R.T.,
1995; Kobayashi, K., et al., 1994). They are important in the treatment of a wide variety
of cancers, including carcinomas of the breast, lung, thyroid and stomach, as well as
Hodgkin's disease, non-Hodgkin's lymphoma, myeloma, acute lymphocytic and
myelogenous leukemia, and sarcomas of various sites.
1.3.4 Plant-Derived Agents
Plants are considered a valuable resource for the discovery and development of
novel, naturally derived agents. To date, several plant-derived anticancer drugs are
administered as part of standard chemotherapeutic regimens, including etoposide, the
vinca alkaloids and taxol (Agarwala, S.S., 1994). Plant-derived agents exert their
neoplastic effects through several mechanisms including inactivation of topoisomerase II,
promotion of microtubule assembly and binding oftubulin. These agents are widely used
in the therapy of the leukemias, Hodgkin's disease, non-Hodgkin's lymphoma, testicular
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cancer, small cell lung cancer, breast cancer, refractory ovarian carcinoma and childhood
tumors.
1.4 Taxol
Taxol is one of the most intriguing anticancer drugs to enter the clinical arena in
many years. It was discovered as part of the new cancer drugs screening and discovery
program of the U.S. National Cancer Institute (NCI) in the 1960s (Panchagnula, R.,
1998). In this program, the NCI collected and screened more than 35,000 plant specimens
from around the world with the hope of discovering new cytotoxic entities (Bissett, D., et
aI., 1993). Among these was the crude extract from the bark of the Taxus brevifolia
(Pacific or Western Yew). This extract showed antitumor activity against several cancer
cell lines and the chemical structure of the active ingredient was identified as taxol
(Panchagnula, R., 1998). Despite its novel structure, and apparent in vitro activity, little
interest was shown in developing taxol further at that time due to its scarcity, problems
with formulation and the mistaken assumption that its mechanism of action was similar to
that of other microtubule-affecting agents, such as the vinca alkaloids (panchagnula, R.,
1998; Bissett, D., et aI., 1993). However, following the discovery oftaxol's unique
mechanism of action in 1979, interest was rekindled and the first clinical trials began in
1983. Since then, taxol has been approved by the U.S. Food and Drug Administration
(FDA) to treat ovarian, breast and non-small lung carcinomas as well as acquired
immunodeficiency syndrome (AIDS) related Kaposi's sarcoma (He, L., 2001; Rowinsky,
E.K., 1997).
1.4.1 Chemistry of Taxol
The chemical name oftaxol is 5B, 20-epoxy-1, 20., 4, 7B, lOB, 13a-hexahydroxytax-
11-en-9-one 4, 10-diacetate-2-benzoate 13-ester with (2R, 3S)-N-benzoyl-3-
phenylisoserine (panchagnula, R., 1998). It occurs as a white to off-white crystalline
powder with the empirical formula C47HsIN014 and a molecular weight of 853.9 daltons
(Kohler, D.R., et al., 1994). Structurally, taxol differs from other currently available
anticancer drugs (Gregory R.E., et aI., 1993; Kingston, D.G.!., 1991). It is a complex
diterpene molecule with a taxane ring structure fused with a four-membered oxetane ring,
an ester side chain at C-13 and a benzoyl side-chain at the C-2 position (Figure 1.2.)
(Burris, H.A. 3rd, 1994). Structure-activity relationships have determined that both the
intact taxane ring and the ester side-chain are essential for cytotoxicity (Kingston, D.G.I.,
1994; Gueritte-Voegelein, F., et aI., 1991; Kingston, D.G.!., 1991).
KC~
H
/' /' CHa
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o
Figure 1.2. Chemical Structure of Taxol
(Burris, B.A. 3rd, 1994)
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1.4.2 Taxol Formulation and Dosing
A major problem encountered in the development of taxol for clinical use was its
insolubility in water (DOff, R.T., 1994). As a result, taxol is formulated in 50%
cremophor EL and 50% ethanol for intravenous administration (Bissett, D., et aI., 1993).
Cremophor EL, a non-ionic surfactant, is a polyoxyethylated castor oil that has been used
to dissolve several other water-insoluble drugs, including cyclosporine, teniposide and
diazepam (Doff, R.T., 1994). Despite its widespread use as a vehicle for many drugs,
cremophor EL has been implicated in a variety of toxic side effects and is thought to be
responsible for the hypersensitivity reactions seen in some patients undergoing taxol
treatment (He, L., et aI., 2001; Rowinsky, E.K., 1997). As a result, premedication with
corticosteroids and antihistamines is mandatory prior to chemotherapy with taxol and has
reduced the incidence of serious hypersensitivity reactions to less than 5% (Bissett, D., et
aI., 1993; Rowinsky, E.K., et al., 1993; Weiss, R.B., et aI., 1990). In cases of severe
hypersensitivity reactions, it has been advised that taxol should be discontinued
immediately (Kohler, D.R., et aI., 1994; Gregory, R.E., et aI., 1993). Many efforts have
been made through chemical modification to increase taxol' s aqueous solubility while
retaining cytotoxic activity, but as of yet these analogues have not clinically replaced the
taxol:cremophor EL formulation.
Paclitaxel® (the only available formulation oftaxol) is formulated as a clear,
colorless to slightly yellow viscous and concentrated solution containing 6 mg/mL taxol,
527 mg/mL cremophor EL polyoxyethylated castor oil and 49.7% (v/v) dehydrated
alcohol, USP (panchagnula, R., 1998; Goldspiel, B.R., 1994). Taxol is packaged in a
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single dose of5 mL per vial containing 30 mg oftaxol (Kohler, D.R., etal., 1994). Prior
to administration by intravenous infusion, taxol concentrate is diluted for injection with
0.9% sodium chloride injection or 5% dextrose injection or 5% dextrose and 0.9%
sodium chloride injection, or 5% dextrose in Ringer's injection to a final taxol
concentration of 0.3-1.2 mg/mL (Panchagnula, R., 1998). Taxol is then infused
intravenously at a dose of 135 or 175 mg/m2 as a 3- or 24-hour-infusion every 3 weeks.
Larger doses and longer infusion periods have also been used. However, optimal dosage
and schedule for taxol as a single agent and in combination chemotherapy has not yet
been established (Goldspiel, B.R., 1994).
1.4.3 Taxol-Mechanisms of Action
Taxol has a unique mechanism of action that differs from that of other anticancer
drugs. The target oftaxol is microtubules, which are essential self-assembling and self-
disassembling proteins that are involved in various cellular functions, such as motility,
ingestion of food, regulation of cell form, sensory transduction and spindle formation
during cell division (panchagnula, R., 1998; Kohler, D.R., et aI., 1994; Horwitz, S.B.,
1992; Manfredi, ],]" et aI., 1984). At any time during the course of the cell cycle, there is
a constant state of dynamic equilibrium between microtubules and tubulin dimers, the
structural units polymerized to form microtubules (Kohler, D.R., et ai., 1994). Taxol
disrupts this dynamic equilibrium, shifting it toward microtubule assembly, by aiding the
polymerization of tubulin dimers to form microtubules, even in the absence of factors that
are normally required for microtubule assembly (e.g. guanosine 5'-triphosphate and '
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microtubule-associated proteins) and then stabilizes the microtubules against conditions
favoring depolymerization, such as low temperature and high calcium concentrations
(Figure 1.3.) (He, L., et ai., 2001; Panchagnula, R., 1998; Kohler, D.R., et aI., 1994). This
results in the formation of abnormal cytoskeletal structures that are not only very stable
but also dysfunctional (Rowinsky, E.K., et aI., 1995; Jordan, M.A., et aI., 1993). These in
vitro activities are facilitated by the binding of taxol within the NH2-terminal 31 amino
acids of B-tublin (Rao, S., et ai., 1994). Although the precise mechanism of action of
taxol is not entirely clear, it is thought that taxol induces cytotoxicity by blocking the cell
cycle at G2 or M phase, thereby inhibiting cell replication and mitosis (Panchagnula, R.,
1998; Kohler, D.R., etai., 1994).
POLYMERIZATION
TUBUUN DIERS
(a,Il)
DEPOLYMERIZATION
Figure 1.3. Mechanism of Action of Taxol
(panchagnula, R., 1998)
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Even though the principle cellular target for taxol is the tubulinlmicrotubule system,
recent studies have demonstrated an increasing number ofnonmicrotubule effects (Fojo,
T., et al., 2000). Taxol has been demonstrated to inhibit tumor angiogenesis, an event
critical for supporting tumor growth and progression (Blajeski, A.L., et aI., 2001; Lau,
D.H., et aI., 1999; Klauber, N., et aI., 1997; Belotti, D., et al., 1996). In addition, taxol
induces expression of tumor necrosis factor-a., activates early response genes and alters
macromolecular trafficking through the nuclear pore complex (Blajeski, A.L., et aI.,
2001; Theodoropoulos, P.A., et aI., 1999; Moos, P.l, et al., 1998; Burkhart, C.A., et aI.,
1994). Numerous studies have also demonstrated activation ofa variety of signal
transduction pathways, including Raf-l and c-Jun N-terminal kinase following addition
oftaxol (Blajeski, A.L., et al., 2001; Fojo, T., et aI., 2000; Shtil, A.A., et aI., 1999;
Amato, S.F., et aI., 1998; Blagosklonny, M.V., et al., 1996). Additionally, several
laboratories have demonstrated that taxol is able to induce intemucleosomal DNA
fragmentation and other characteristic features of apoptosis (Blajeski, A.L., et aI., 2001;
Fan, W., 1999; Saunders, D.E., et aI., 1997; McCloskey, D.E., et aI., 1996; Liu, Y., et aI.,
1995). Furthermore, reports have indicated that taxol has numerous effects on proteins
involved in apoptosis, such as the phosphorylation ofBcl-2, an event that abrogates its
antiapoptotic activity (Blagosklonny, M.V., 2001; Cheng, S.C., et al., 2001; Haldar, S., et
al., 1996; Blagosklonny, M.V., et al., 1996). These results suggest that taxol possesses
the ability to induce apoptosis. Specifically, research groups have reported that taxol can
induce apoptosis in MCF-7 and MDA-MB-468 human breast cancer cells (Saunders,
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D.E., et aI., 1997; McCloskey, D.E., et aI., 1996). Whether these are primary effects of
taxol or secondary effects of other alterations remain to be elucidated.
1.4.4 Drawbacks of Taxol
1.4.4.1 Development ofDrug Resistance
Two mechanisms of acquired resistance to taxol have been characterized (Kohler,
D.R., et aI., 1994; Kuhn, lG., 1994; Rowinsky, E.K., 1993). The first mechanism
involves the development of altered u- and p-tubulin proteins, which impair the ability of
tubulin dimers to polymerize to form microtubules. These cells lack normal microtubules
in their mitotic spindles when grown in the absence oftaxol. Subsequently, these cells
become partly or completely dependent on the presence of taxol for microtubule
assembly to progress normally. As a result, this mechanism of resistance confers 2- to 3-
fold taxol resistance. The second mechanism of acquired taxol resistance involves the
multidrug resistance (MDR) phenotype, which gives varying degrees of cross-resistance
to taxol and many other classes of drugs, including the vinca alkaloids, colchicines,
doxorubicin, daunorubicin, and etoposide. The presence of this phenotype results in a
decreased accumulation of drug within the cell due to an overexpression ofP-
glycoprotein, a transmembrane protein which functions as a drug efllux pump. Cell lines
expressing the MDR phenotype have been developed that are 800-fold resistant to taxol.
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1.4.4.2 Availability of Taxol
Throughout its development, taxol has been greatly hampered by the limited supply
of its source materials. Until recently, the only source oftaxol was from the bark of the
Taxus brevifalia (Pacific or Western Yew) (Blume, E., 1991). The Yew is a slow growing
tree which dies once its bark is removed, thus making it difficult to obtain enough taxol
to meet the demands (Panchagnula, R., 1998; Kohler, D.R., et aI., 1994). In recent years,
improvements have been made in production technology to increase the supply oftaxol
from the Yew's bark (panchagnula, R., 1998). But still, 3000 trees must be sacrificed in
order to obtain 1 kg oftaxol, enough to treat about 500 people (panchagnula, R., 1998;
Blume, E., 1989).
In an attempt to alleviate the drug supply problem, research programs were
implemented to evaluate alternative sources oftaxol (Kohler, D.R., et aI., 1994). A
semisynthetic method using a precursor, baccatin III, extracted from the needles and
twigs of more prevalent Yews, including ornamental and commercially cultivated
varieties has been developed (panchagnula, R., 1998; Kohler, D.R., et aI., 1994). Since
twigs and needles are renewable and does not cause the death of the tree, this method
provides a means to ensure continuing supplies oftaxol. For example, Docetaxel
(Taxotere®), a semisynthetic analogue oftaxol, is produced by attaching a semisynthetic
side-chain to 10-deacetylbaccatin III, which is readily available, in yields of about 1 kg
per 3000 kg ofneedles, from Taxus baccata (European Yew) (Panchagnula, R., 1998).
Docetaxel inhibits microtubule depolymerization in a similar manner to taxol and was
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shown to have a broad spectrum of activity in preclinical studies (Ringel, I., et aI., 1991;
Bissery, M.C., et aI., 1991).
Taxus cell culture, by a fungal endophyte, Taxomyces andreanae, is also a
promising approach to meeting the growing demands for taxol (panchagnula, R., 1998;
Kohler, D.R., et aI., 1994; Stierle, A., et aI., 1993). Although the amount oftaxol
produced with this technique is low, studies have shown that the addition of methyl
jasmonate, which plays an important role in signal transduction, can increase the
production oftaxol and baccatin ill (panchagnula, R., 1998). Sustained production of
taxol by semicontinous perfusion nodule cultures also appears to be another approach to
produce large quantities. Although this is a relatively new research area, the results are
very promising and the technique appears to be a bright prospect for increasing
production of taxol and baccatin III.
Although the total synthesis of taxol has been achieved, its synthesis on an
industrial scale is very difficult and may not be commercially feasible (panchagnula. R.,
1998; Nicolaou, K.C, et al., 1994). Furthermore, taxol analogues are also a challenge due
to the construction of the taxane framework with a four-membered oxetane ring and an
ester side chain at C-13, both ofwhich are essential for cytotoxic activity (panchagnula,
R., 1998). Thus, with today's technology, the replacement of natural sources oftaxol with
totally synthetic taxol does not seem to be commercially feasible. Consequently, major
efforts are under way to develop taxol using the former approaches.
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1.4.4.3 Delivery Problems
Another major hurdle for successful treatment with taxol is its delivery. Since taxol
is insoluble in water, it is formulated in 50% cremophor EL and 50% ethanol for
intravenous administration (panchagnula, R., 1998; Goldspiel, B.R., 1994; Bissett, D., et
al., 1993). However, it is obvious from the problems seen in present-day therapy, such as
toxic side effects and hypersensitivity reactions, the necessity of developing an improved
delivery system for taxol that is devoid of cremophor EL (Panchagnula, R., 1998).
Researchers are also searching for formulations that would allow production on a larger
scale and stability for longer periods of time. Several attempts have been made to deliver
taxol by newer drug delivery systems such as nanocapsules, liposomes, enzyme-
activatable prodrugs in conjugation with antibodies, albumin conjugates, parenteral
emulsion, water-soluble prodrugs, microspheres and cyclodextrins. However, these drug
delivery systems have had only limited success. None of these have reached the stage of
replacing cremophor-based vehicles in clinical situations. The search for newer drug
delivery systems for taxol is an ongoing project.
1.5 Apoptosis
Based on morphological, biochemical, and molecular criteria, two distinct modes of
cell death can be recognized: apoptosis and necrosis (Gorczyca, W., et al., 1998; Kerr,
IF.R., et al., 1972). Apoptosis, from the Greek word for, "dropping off" or "falling off"
of petals from flowers or leaves from trees, is used to describe a process in which a cell
actively participates in its own demise (Gorczyca, W., et a!., 1998; Yeh, E.T.H., 1998). It
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is recognized to play crucial roles in a wide variety of normal physiological processes
including embryogenesis, development, and tissue homeostasis of multicellular
organisms (Pinton, P., et aI., 2001~ Kerr, IF.R., et al., 1972). Moreover, dysregulation of
apoptosis has broad ranging pathological manifestations and has been associated with
Alzheimer's, Hodgkin's, transplant rejection, cancer and AIDS (Kitamura, Y., et aI.,
1998~ Lin, T., et aI., 1998~ Wang, L., et al., 1998~ Lorenzen, J., et aI., 1997~ Thompson,
C.B., 1995~ Carson, D.A., et aI., 1993). Consequently, apoptosis is a process of major
biomedical interest.
Necrosis, which typically occurs as a result ofgross injury to the cell, is distinct
from apoptosis in a number of important ways (Darzynkiewicz, Z., et aI., 1997). Necrosis
is a chaotic process and lacks the tight regulation and organization of apoptosis (Dixon,
S.C., et aI., 1997). Furthermore, it's an unplanned, passive process as opposed to
apoptosis, which is an active process requiring the participation of affected cells in their
own death (Gorczyca, W., et aI., 1998). Another primary difference between these two
modes of cell death is the physical and biochemical factors that either suppress or induce
an inflammatory reaction (Dixon, S.C., et aI., 1997). Necrotic cell death begins with the
swelling of the cell and mitochondrial contents, followed by rupture of the plasma
membrane (Darzynkiewicz, Z., et aI., 1998~ Majno, G., et al., 1995). As a result, necrosis
can trigger an inflammatory reaction in the surrounding tissue and often results in scar
formation due to the release of cytoplasmic contents. In contrast, in apoptosis, the dying
cells become fragmented into "apoptotic bodies" which are rapidly eliminated by
phagocytic cells without eliciting inflammatory damage to surrounding cells. These and
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other morphological, biochemical and pathological characteristics that differentiate these
two modes of cell death are described in Table 1.1.
Necrosis Apoptosis
Table 1.1. Differential Features and Significance of Necrosis and Apoptosis
(Adapted from http://www.roche-applied-science.com)
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In recent years, increasing evidence is beginning to establish that many and perhaps
all chemotherapeutic agents affect tumor cell killing in vitro and in vivo through
launching the mechanisms of apoptosis. This was first observed in a landmark study
investigating the mechanism of action of etoposide, camptothecin and other cytotoxic
anticancer drugs (Hannun, Y.A., 1997; Kaufmann, S.H., 1989). In this study, it was
observed that treatment ofhuman Ill.--60 and KG1A leukemia cells with etoposide
resulted in the rapid induction of intemucleosomal DNA fragmentation. This observation
raised the possibility that etoposide caused apoptotic cell death. Since then, the spectrum
of chemotherapeutic agents causing apoptosis has expanded progressively and includes
inhibitors of protein and RNA synthesis, dihydrofolate reductase inhibitors,
topoisomerase I and II targeting drugs, nucleoside analogues, microtubule poisons,
alkylating agents, cisplatin, ionizing radiation and hydrogen peroxide (Hannun, Y.A.,
1997; Fisher, D.E., 1994). This list continues to expand as more evidence supporting the
role of apoptosis in chemotherapy continues to grow.
1.6 Techniques to Assess Apoptosis
The earliest techniques to detect apoptosis were based mainly on morphology.
However, during the last decade, techniques designed to identify, quantitate and
characterize apoptosis have been extended to biochemistry, molecular biology and
immunology as we learn more about the complex mechanisms that underlie this process.
In the next sections, some of the different techniques utilized to assess apoptosis will be
discussed.
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1.6.1 Morphological Assessment
A cell undergoing apoptosis proceeds through three phases of morphological
change. In the first, there is reduction in nuclear size, nucleolar disintegration and
condensation of chromatin (Arends, M.J., etal., 1991; Arends, M.J., etal., 1990). The
condensation begins at the margin of the nucleus with regions of condensed chromatin
acquiring a concave shape resembling a half-moon, horseshoe or sickle (Daryznkiewicz,
Z., et aI., 1997). Additionally, there is a loss of contact between apoptotic cells and their
neighboring cells (Dixon, S.C., et aI., 1997). This detachment isolates the dying cells as
they begin simultaneously shedding specialized surface elements such as cell-cell
junctions and microvilli. Furthermore, the cell undergoes a rapid, yet selective, voiding of
water and ions without a corresponding loss of macromolecules or organelles. This
imbalance leads to condensation of the cytoplasm and compaction of organelles. The
result is an overall shrinkage of cell volume and a sudden increase in intracellular density
causing a change in cell shape and size. As a consequence, the cells may become
elongated and generally are smaller.
In the second phase (which may overlap with the first), there is budding and
separation ofboth nucleus and cytoplasm into multiple membrane-bound apoptotic
bodies with intact organelles that mayor may not contain nuclear fragments (Arends,
M.l, et al., 1991; Arends, M.l, et aI., 1990). These apoptotic bodies may be shed from
epithelial surfaces or quickly phagocytosed in vivo by their nearest neighbor or by
macrophages without triggering an immune reaction.
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In the third phase, there is progressive breakdown of residual nuclear and
cytoplasmic structures (Arends, M.l, et aI., 1991; Arends, M.l, et aI., 1990). In cultured
cells, this is seen as a rupturing of the plasma membrane, resulting in permeability to vital
dyes. Eventually, all membranes disappear, organelles become unrecognizable and the
appearance is that of a lysosomal residual body.
Numerous methods can be employed to assess these morphological changes,
however light microscopy still remains the "gold standard" (Gorczyca, W., et aI., 1998).
Many morphological features of apoptosis, such as cell shrinkage, membrane blebbing,
chromatin condensation, nuclear fragmentation and formation of apoptotic bodies can be
seen through examination of cells by light microscopy. Electron microscopy can also be
utilized to detect morphological changes on the subcellular level, thus increasing
sensitivity and specificity (van Heerde, W.L., et aI., 2000). Furthermore, time-lapse
videomicroscopy is an effective tool for assessing morphological features of apoptosis,
particularly membrane blebbing (Hall, P.A., 1999).
Numerous dyes and stains are also utilized to assess apoptotic nuclear morphology
by microscopy. Haemotoxylin, thionin blue and eosin are examples of nuclear
counterstains used for light microscopic examination (Wilson, J. W., et aI., 1999).
Fluorescent nuclear stains, such as 4', 6-diamidino-2-phenylindole (DAPI) and Hoechst
33258 and 33342 are also commonly used to assess apoptosis. Hoechst 33342 is a dye
that is readily incorporated into the nuclei of early apoptotic cells rather than the nuclei of
non-apoptotic cells (Strobl, lS., et aI., 1998; Eguchi, Y., et aI., 1997). As a result, the
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Hoechst dye stains morphologically normal nuclei dimly blue, whereas apoptotic nuclei
demonstrate condensed, smaller, and very intensely bright blue nuclei.
Changes in morphology of apoptotic cells can also be assessed using flow
cytometry due to a change in light-scattering properties (van Heerde, W.L., et a/., 2000;
van Engeland, M., et aI., 1996; Darzynkiewicz, Z., et aI., 1992). During the apoptotic
process, cells shrink and subsequently condense, resulting in a shift in the cytogram from
high forward/low side scatter to low forward/high side scatter. This technique can be
employed on relatively large number of cells in a short period of time and thus is an
excellent tool for assessment of apoptosis.
Despite the versatility of morphological assessment, there are several limitations
associated with this technique. Firstly, flow cytometric analysis of morphology generally
requires cells to be in suspension and thus limits its applicability for routine use whereas
microscopic analysis is elaborate, time consuming and cumbersome for quantitative
analysis (van Heerde, W.L., et a/., 2000; van Engeland, M., et a/., 1996). Also, a
disadvantage of light microscopy is its low sensitivity, especially due to the speed of
apoptosis and the rapid clearance of apoptotic cells from tissues by phagocytosis, which
can be completed within 30-60 minutes from the onset of apoptosis (van Heerde, W.L., et
aI., 2000). In addition, late apoptotic cells may not be detected by light microscopy due to
their small size (Singh, N.P., 2000). Thus, it is very well possible that light microscopy
may illustrate only the tip of the iceberg (van Heerde, W.L., et a/., 2000; Majno, G., et
aI., 1995; Kerr, IF.R., et aI., 1972). Finally, it may be difficult to detect the early stages
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ofapoptosis with little or no morphological changes, which may affect quantitative
analysis and perceived apoptotic index (Singh, N.P., 2000; Au, lL.S., et aI., 1997).
1.6.2 Annexin V Assay
Another measurable feature of apoptosis is the loss of plasma membrane
asymmetry. The cell membrane is composed of four major phospholipids:
phosphatidylcholine, phosphatidylethanolamine, sphingomyelin and phosphatidylserine
(PS) (Blankenberg, F.G., et aI., 2000). These phospholipids are distributed
asymmetrically throughout the plasma membrane, with phosphatidylcholine and
sphingomyelin predominately on the outer leaflet and phosphatidylethanolamine and PS
on the inner leaflet of the plasma membrane (van Engeland, M., et aI., 1998; Devaux,
P.F., 1991). This phospholipid asymmetry is generated and maintained by membrane
proteins called flippases, which facilitate the translocation of lipid molecules from one
leaflet to the other (van Engeland, M., et aI., 1998; Higgins, C.F., 1994).
Early in apoptosis, before the loss of plasma membrane integrity, PS becomes
translocated from the inner to the outer leaflet of the plasma membrane (Blankenberg,
F.G., et al., 2000; van Engeland, M., et aI., 1998; Vermes, I., et aI., 1995; van Engeland,
M., et aI., 1996; Koopman, G., et al., 1994; Fadok, V.A., 1992). While the exact
mechanism by which PS becomes externalized is not entirely clear, it is thought to arise
due to an inhibition of the aminophospholipid translocase and subsequent activation of
scramblase, a plasma membrane protein which facilitates the rapid mobilization ofPS to
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the external leaflet of the plasma membrane upon elevation of internal Ca2+ concentration
(Denecker, G., et aI., 2000).
The exposure ofPS to the external surface of the cell is a general feature of
apoptosis (Blankenberg, F.G., et aI., 2000). It is thought to serve as a signal to
neighboring cells that PS-expressing cells are undergoing apoptosis. It is also thought to
playa functional role in the recognition and removal of apoptotic cells by macrophages,
which possess a PS receptor on their plasma membrane (Tzima, E., et aI., 2000; Fadok,
V.A., 1998; Koopman, G., et aI., 1994; Fadok, V.A., et aI., 1992). This has important
implications as the recognition and phagocytosis of apoptotic cells prior to cell lysis is
crucial in the avoidance of tissue damage and inflammation associated with necrosis
(Fadok, V.A., 1992; Wyllie, A.H., et aI., 1980).
In addition to PS externalization, the apoptotic cell undergoes other structural
changes in its plasma membrane to signal its process of dying to the environment (van
Engeland, M., et aI., 1996). These include a change in carbohydrate profile, a change in
surface charge, and a shift from tightly to loosely packing of the plasma membrane
phospholipids (van Engeland, M., etal., 1996; Fadok, V.A., etal., 1992; Savill, IS., et
aI., 1989; Duvall, E., et aI., 1985; Morris, R.G., et ai, 1984). The former two changes
have not yet formed the basis of an apoptosis assay. However, the loose packing of
phospholipids has been probed flow cytometrically by Merocyanine 540, which probably
intercalates in these membranes (van Engeland, M., et aI., 1996; Mower, D.A. Jr., et aI.,
1994).
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Annexin V is a 35-36 kilodalton (kDa) Ca2+-dependent, phospholipid-binding
protein that has a high affinity for PS, and binds to cells with exposed PS (van Engeland,
M., et aI., 1998; Vermes, I., et aI., 1995; Koopman, G., et aI., 1994). Based on these
findings and the phenomenon that PS is exposed during apoptosis, a method using
annexin V conjugated to fluorochromes, such as fluorescein isothiocyanate (FITC), to
detect apoptosis was developed (Koopman, G., et aI., 1994). These formats retain their
high affinity for PS and hence serve as sensitive probes for detection of apoptosis.
The exposure ofPS to the extemalleaflet of the plasma membrane is not only
unique to apoptosis, but also occurs during necrosis (Vermes, I., et aI., 1995). A major
difference between the two is that in the early stages of apoptosis the cell membrane
remains intact, whereas at the onset of necrosis, the cell membrane loses its integrity and
becomes leaky. As a result, the annexin V assay must be performed in conjugation with a
dye exclusion test in order to establish cell membrane integrity (Darzynkiewicz, Z., et al.,
2001; Vermes, I., et aI., 1995). Therefore, the simultaneous application of annexin V with
a vital dye such as propidium iodide (PI) makes it possible to identify unaffected,
nonapoptotic cells (annexin V negative/ PI negative) from early apoptotic cells (annexin
V positivelPI negative) and late apoptotic as well as necrotic cells (annexin V positivelPI
positive).
The annexin V assay is a widely used method to assess apoptosis facilitated by the
observation that translocation ofPS seems to be a universal phenomenon during
apoptosis (van Engeland, M., et aI., 1998). It has been detected in mammalian, insect, and
plant cells under the action of most, if not all, triggers of apoptosis. Furthermore, the
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annexin V assay can identify apoptotic cells at an earlier stage than assays based on
morphological as well as nuclear changes, since loss of plasma membrane asymmetry is a
rather early phenomenon in the apoptotic process.
Despite these advantages, there are limitations associated with the annexin V assay.
One weakness is its limited applicability (van Engeland, M., et aI., 1999). For example,
in frozen and paraffin-embedded tissue sections, annexin V also detects PS on the inner
leaflet of the plasma membrane. Therefore, in these situations another apoptosis detection
system has to be employed. Additionally, the annexin V assay cannot differentiate
between necrotic cells and cells that have already undergone apoptosis, because in both
cases the dead cells will stain with annexin V (positive) and PI (positive)
(Darzynkiewicz, Z., et aI., 2001). This in tum, may affect quantitative analysis and
perceived apoptotic index.
1.6.3 DNA Fragmentation
One of the most characteristic features of apoptosis is DNA fragmentation, a
process that results from the activation of endogenous endonucleases (Walker, P.R., et
aI., 1999; Walker, P.R., et al., 1997; Walker, P.R., et aI., 1994). These endonucleases
cleave DNA in a two-step process, characterized by the size-classes ofDNA fragments
produced. In the first step, DNA is cleaved into high molecular weight (BMW)
fragments of 50-300 kilobase pairs (kbp). This cleavage is sufficient to destroy the
normal pattern of chromosome organization, resulting in partial condensation of
chromatin. The second step ofDNA fragmentation, which does not occur in all cell types,
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involves the subsequent cleavage of the BMW fragments to smaller fragments and the
classical oligonucleosome DNA "ladder". Significantly, only the first step ofDNA
fragmentation is considered essential for cell death, as some cells, such as MCF-7, never
produce DNA "ladders" although they show the classic morphological features of
apoptosis. Moreover, in cells that usually do produce DNA "ladders", blocking the
second step ofDNA fragmentation does not prevent either chromatin condensation or
apoptosis.
Currently, numerous techniques are available to assess DNA fragmentation.
Internucleosomal DNA fragmentation can readily be detected by agarose gel
electrophoresis (Darzynkiewicz, D., et al., 2001; Al-Rubeai, M., 1998; Gong, 1., et aI.,
1994; Arends, M.J., et a/., 1990). Activation of endonucleases during apoptosis leads to
the generation of discontinuous DNA fragments representing nucleosomal- and
oligonucleosomal-sized DNA sections. These fragments generate a characteristic
"ladder" pattern during agarose gel electrophoresis. In contrast, DNA fragments produced
during necrosis are not as extensive and are heterogenous in size, resulting in a smear on
agarose gels. Thus, due to the characteristic "ladder" pattern revealed by agarose gel
electrophoresis, this technique is widely used to assess apoptosis.
In situ DNA strand breaks generated during apoptosis can also be detected and
identified using two techniques (Darzynkiewicz, Z., et aI., 1997; Li, X., et a/., 1996). The
first technique is based on measurement of cellular DNA content; cells are permeabilized
or prefixed, hydrated, stained with any DNA-specific fluorochrome and subjected to
DNA content analysis (Darzynkiewicz, Z., et aI., 1997; Li, X., et aI., 1996; Walker, P.R.,
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et al., 1994). In apoptotic cells, however, cell permeabilization or alcohol fixation does
not fully preserve the degraded DNA. Consequently, this fraction ofDNA leaks out
during the hydration and staining steps. Hence, apoptotic cells contain reduced amounts
ofDNA and therefore stains less intensely with any DNA fluorochrome. As a result,
apoptotic cells can be differentiated from live cells in DNA histograms as cells with DNA
stainability ("sub-GI" peaks) often lower than that OfGI cells. This approach offers the
advantage of simplicity and applicability as it can be employed with any DNA
fluorochrome or instrument. The second technique is based on specific labeling ofDNA
strand breaks that are generated during apoptosis. In this technique, cells are pre-fixed
with a cross-linking fixative and the 3'-OH ends of the DNA strand breaks are detected
by labeling with biotin- or digoxygenin-conjugated deoxynucleotides in a reaction
catalyzed by exogenous terminal deoxynucleotidyl transferase (TdT) or DNA
polymerase (nick translation). The former assay based on the use of TdT, commonly
known as TUNEL (TdT-mediated deoxyuridine triphosphate-biotin nick-end labeling)
offers a better discrimination between apoptotic and nonapoptotic cells than the nick
translation assay.
There are numerous limitations associated with the various techniques to assess
DNA fragmentation. Although the characteristic "ladder" pattern ofDNA fragmentation
is one of the most common methods to assess DNA fragmentation, it has several
weaknesses. First, it should be noted that some cell types, such as MCF-7 and DU145,
show almost no DNA fragmentation, although they show the classical morphological
features of apoptosis (Oberhammer, F., et al., 1992; Cohen, G.M., et aI., 1992). Second,
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agarose gel electrophoresis detection ofDNA fragmentation involves a DNA isolation
procedure from millions of cells and thus the results obtained cannot be quantified
(Singh, N.P., 2000). Third, agarose gel electrophoresis requires large numbers of
apoptotic cells and thus is difficult to detect a small number of apoptotic events. A
limitation of the DNA extraction method is its low specificity (Elstein, K.H., et aI.,
1994). In addition to apoptotic cells, the sub G1 peak can represent cells with lower DNA
content, mechanically damaged cells or cells with different chromatin structure in which
accessibility ofDNA to the fluorochrome is restricted (Darzynkiewicz, Z., et al., 1997).
Furthermore, although the TUNEL assay is sensitive, this method is associated with a
number of artifacts, as it labels DNA strand breaks from any insult, in both apoptotic and
nonapoptotic cells (Singh, N.P., 2000~ Kockx, M.M., et aI., 1998). In addition, the
TUNEL assay frequently results in the loss of frail apoptotic cells during handling.
Moreover, it requires elaborate handling of cells to incorporate hapten-labeled
nucleotides at the sites ofnicked DNA (van Engeland, M., et aI., 1996). Finally, the
TUNEL assay does not discriminate between early and late stages of apoptosis and does
not provide information on the integrity of the plasma membrane.
1.6.4 PARP Cleavage Assay
Poly(ADP-ribosylation) is a post-translational modification of proteins that is
involved in many critical processes within the eukaryotic cell, including DNA repair and
replication, transcription and cell death (Soldani, C., et aI., 2002~ Soldani, C., et aI.,
2001). One of the best-known poly (ADP-ribosylating) enzymes is poly (ADP-ribose)
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polymerase (pARP), a 116 kDa zinc-finger nuclear enzyme involved in DNA repair and
activated in response to DNA damage (Soldani, C., et a/., 2002; Soldani, C., et a/., 2001;
Shall, S., et a/., 2000; Soldatenkov, V.A., et a/., 2000; Aoufouchi, S., et a/., 1999; Duriez,
P.l, et aI., 1997). At a site ofDNA breakage, PARP binds very tightly to DNA strand
breaks or nicks, and uses ~NAD+ as a substrate for transferring ADP-ribose moieties to
nuclear proteins including topoisomerases, histones and PARP itself.
Recently, it has been reported that PARP is a target of the cysteine-aspartic acid
specific proteases (caspases) associated with apoptosis (Soldani, C., et aI., 2002;
Aoufouchi, S., et aI., 1999; Duriez, P.l et aI., 1997; Sallmann, F.R., et a/., 1997; Patel,
T., et aI., 1996). Early in apoptosis, caspase-3 and caspase-7 cleave the intact 116 kDa
PARP at the DEVD site between Asp214 and Gly215, to generate 85- and 25- kDa
fragments. This process separates the amino-terminal DNA binding domain of the
enzyme from the carboxy-terminal catalytic domain resulting in a loss of normal function
ofPARP. Although the exact role ofPARP in apoptosis remains to be elucidated, PARP
cleavage is considered a marker of apoptosis.
Numerous techniques can be employed to assess PARP cleavage. Monoclonal or
polyclonal anti-PARP antibodies can be used for immunoblotting, immunoprecipitation,
and immunohistochemical visualization ofPARP or its fragments (Duriez, P.l, et al.,
1997). Autoimmune antisera that recognize PARP can also be utilized. Furthermore, the
availability of the cDNA has permitted synthesis of radioactive PARP for in vitro
cleavage assays. Radioactive PARP allows the simultaneous detection of all fragments of
PARP and alleviates the problems associated with specificity and epitope recognition that
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can limit the detection capacity with antibodies. Moreover, fragments ofPARP with the
intact C-terminus can also be detected due to their enzymatic activity. Specifically, the
89-kDa apoptotic fragment can be detected through its capacity to make the polymer of
ADP-ribose from radioactive or nonisotopic NAD. Finally, flow cytometric analysis of
cells differentially stained for PARP p89 and DNA makes it possible to score and identify
apoptotic cells and also allows one to correlate apoptosis with the cell cycle or DNA
ploidy (Darzynkiewicz, Z., et aI., 2001).
Compared with other detection methods, PARP cleavage is a relatively simple and
sensitive marker for apoptosis. It can be detected very early during apoptosis and even
when very few cells in the total population are undergoing apoptosis (Duriez, P.I., et aI.,
1997). For instance, PARP cleavage can be detected by immunoblotting within 15-30
minutes during etoposide-induced apoptosis ofHL-60 cells, while intemucleosomal
degradation ofDNA cannot be detected until after 2-3 hours.
Despite the advantages of using PARP cleavage in the assessment of apoptosis,
there are limitations associated with this technique. In some models of apoptosis, PARP
is not cleaved to form the signature 89-kDa fragment, such as the case during
camptothecin-induced apoptosis ofHep 3B cells (Adjei, P.N., et aI., 1996). Furthermore,
recent studies have demonstrated that PARP-1- cells exhibit a normal apoptotic response
to various stimuli, including TNF-a and anti-FAS treatment, suggesting that PARP is
dispensable in various apoptotic pathways (Leist, M., et aI., 1997; Wang, Z.-Q., et aI.,
1997). Finally, in some cases, essentially due to technical drawbacks, PARP cleavage can
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sometimes be detected in non-apoptotic cells (Budihardjo, I.I., eta!., 1998). For these
reasons, apoptosis cannot be assessed by evaluating PARP cleavage exclusively.
1.7 Regulation of Apoptosis
Apoptosis is a higWy regulated process that depends on the expression of a specific
set ofgenes. In recent years, a large number of apoptosis regulators and gene families
comprised mostly of cell death mediators have emerged (Mckenna, S.L., et ai., 1998). In
addition, several oncogenes and tumor suppressor genes have also been implicated in the
modulation of apoptotic pathways.
1.7.1 p53
The p53 tumor suppressor gene is a phosphoprotein barely detectable in the nucleus
of normal cells (Soussi, T., 2000; Levine, A.I., 1997). In response to cellular stress, p53
protein accumulates in the cell nucleus, causing cells to undergo cell cycle arrest to
enable DNA repair, or apoptosis to eliminate defective cells (Herr, I., et ai., 2001; Zomig,
M., et ai., 2001; Levine, A.I., 1997; Thompson, C.B., 1995). These functions are thought
to be achieved due to the transactivational properties ofp53, which activate a series of
genes involved in cell cycle regulation (Herr, I. eta!., 2001; Shen, Y., eta!., 2001;
Zomig, M., et ai., 2001; Hainaut, P., et ai., 2000; Soussi, T., 2000; Mowat, M.R.A.,
1998). Many of these p53 target genes have been identified, and their functions have been
characterized. For instance, p53-induced cell cycle arrest is known to require
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transactivation ofp21 Wafl/Cipl, GADD45 and cyclin G (Herr, I., et aI., 2001; Canman,
C.E., et al., 1995).
How p53 mediates apoptosis is less clear. However, several studies conducted using
various p53 transactivation-defective mutants have shown that p53-induced apoptosis is
dependent on its transcriptional transactivating activity (Herr, 1., et aI., 2001; Shen, Y., et
aI., 2001; Hainaut, P., et aI., 2000; Mowat, M.R.A., 1998). One such transcriptional
target for p53-induced apoptosis is the Bax gene (Herr, 1., et aI., 2001; Shen, Y., et aI.,
2001; Hainaut, P. et aI., 2000; Mowat, M.R.A., 1998; Levine, A.I., 1997; Miyashita, T. et
aI., 1995). Bax is a member of the Bcl-2 gene family that comprises both positive and
negative regulators of apoptosis. Studies have shown that overexpression or induction of
p53 up-regulates Bax and down-regulates Bcl-2, both ofwhich insert into mitochondrial
membranes to inhibit (Bcl-2) or facilitate (Bax) the opening of the mitochondrial
permeability transition pores. In doing so, p53 is thought to promote mitochondrial
leakage of apoptogenic signals. Other proapoptotic members of the Bcl-2 gene family,
such as Bak and Noxa, are also up-regulated by p53. They are thought to function
downstream ofp53 and induce p53-related toxicity. Another potential target for p53
transactivation are death receptors such as KillerfDR5, APOllfas/CD95 and TRill (Shen,
Y., et aI., 2001; Hainaut, P., et aI., 2000; Mowat, M.R.A., 1998). These receptors are
important regulators ofapoptosis and are among the transactivational targets ofp53,
suggesting that p53 may playa role in death receptor-induced apoptosis. Another class of
p53 transactivation targets includes many genes involved in signal transduction
regulation, such as IGF-BP3, PTGF-beta and PERP. These genes are all involved in
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promoting apoptosis, suggesting that p53 may mediate apoptosis by manipulating signal-
transduction pathways. Finally, it has been suggested that some p53 target gene products
regulate the production of reactive oxygen species (ROS), resulting in mitochondrial
membrane changes and cytoplasmic release of apoptogenic signals (Herr, I., et aI., 2001;
Shen, Y., et al., 2001; Hainaut, P., et aI., 2000). Hence, p53 may signal apoptosis through
the production ofROS.
Although p53 is mostly known to activate transcription, it can also repress gene
transcription (Shen, Y., et aI., 2001; Hainaut, P., et aI., 2000; Mowat, M.R.A., 1998).
Studies have shown that p53 represses the expression of a number ofgenes including c-
fos, cyclin A, map 4, interleukin 6 and Bcl-2. Recent studies have also shown that in
response to irradiation, p53 can up-regulate genes involved in cell-cycle arrest and DNA
repair, while repressing genes involved in cell division.
p53 can also induce apoptosis through non-transcriptional mechanisms. For
example, p53 can increase the expression of the cell surface death receptor, CD95 by
facilitating its transport from the Golgi complex (Herr, I., et aI., 2001; Zomig, M., et aI.,
2001). This cell surface redistribution of cytoplasmic CD95 sensitizes cells to CD95-
induced apoptosis and can occur without new RNA synthesis.
Additionally, p53 can contribute to apoptosis by direct signaling at the
mitochondria (Zomig, M., et aI., 2001). Following DNA or hypoxic damage, a small
amount of stress-induced p53 protein is redirected from the nucleus to the mitochondria.
This mitochondrial localization occurs before the release of cytochrome c and procaspase
activation and is blocked by the overexpression of anti-apoptotic Bcl-2 proteins. Studies
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have shown that redirecting p53 from the nucleus to the mitochondria by using
mitochondrial import leader peptides is sufficient to induce apoptosis in p53-deficient
mice, even with a transcriptionally inactive p53 mutant.
Taken together, apoptosis induced by or involving p53 consists of multiple
transcriptional activation-dependent and independent pathways. Given the importance of
p53 on the regulation of apoptosis, growth arrest and DNA repair, additional studies are
required to further elucidate the role ofp53 and its target genes on these cellular
functions.
1.7.2 Cytochrome c
Cytochrome c is an electron transporting protein that normally resides in the space
between the outer and inner membranes of the mitochondria where it plays a critical role
in the process of oxidative phosphorylation and production of cellular adenosine
triphosphate (ATP) (Zornig, M., et aI., 2001; Boyer, P.D., et a/., 1977). In recent years,
an increasing amount of interest has been directed toward the role which cytochrome c
has been demonstrated to play in apoptotic processes. Following exposure to an apoptotic
stimulus, cytochrome c is rapidly released from the mitochondria into the cytosol
(parone, P.A., et al., 2002; Zornig, M., et al., 2001; Tsujimoto, Y., et aI., 2000; Chen, Q.,
et aI., 2000; Jiang, X., et aI., 2000). Once in the cytosol, cytochrome c binds its cytosolic
partner, apoptosis-activating factor 1 (Apaf-1), via the C-terminal WD-40 repeat domain,
and induces the oligomerization of Apaf-1/cytochrome c in the presence of ATP or
dATP. This multimeric complex, called an apoptosome, is sufficient to recruit
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procaspase-9 to the complex and induces auto-activation of the procaspase. Activated
caspase-9 is then released from the Apaf-llcytochrome c complex and activates
downstream caspases such as caspase -3, -6 and -7, which are central executioners of the
apoptotic pathway (Hengartner, M.O., 2000). In addition to triggering caspase activation
and apoptosis, the release of cytochrome c from the mitochondria is thought to have
several other consequences, such as a loss of oxidative phosphorylation and the
generation ofROS (Goldstein, lC., et ai., 2000; Green, D.R., et ai., 1998). These may
contribute to cell death even if caspase function is inhibited.
Despite the importance of this key event in apoptosis, the mechanism by which
cytochrome c is released into the cytosol is not entirely clear. However, several theories
have been proposed (parone, P.A., et ai., 2002; Z6mig, M., et ai., 2001; Tsujimoto, Y., et
ai., 2000, Von Ahsen, 0., et ai., 2000, Bossy-Wetzel, E., et ai., 1999). Two ofthese
theories suggest that cytochrome c release is mediated by physical rupture of the
mitochondrial outer membrane, resulting from mitochondrial swelling. In one theory,
swelling is postulated to result from opening of the permeability transition pore (PTP).
The PTP is a multiprotein complex formed at the contact sites between the inner and
outer mitochondrial membrane. It is composed of many proteins including hexokinase,
voltage dependent anion channel (VDAC), adenine nucleotide translocator (ANT) and
cyclophilin D. Opening of the PTP leads to equilibration of solutes up to 1.5 kDa
between the mitochondrial matrix and the intermembrane space. This results in a loss in
mitochondrial inner membrane potential, uncoupling of the respiratory chain,
mitochondrial swelling and rupture of the outer membrane, leading to the passive release
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of cytochrome c from the mitochondria. This theory has been supported by studies where
cytochrome c was shown to be released from isolated mitochondria by agents that open
the PTP. A second theory for cytochrome c release suggests an initial hyperpolarization
(increase in mitochondrial membrane potential) due to inhibition in mitochondrial
ATP/ADP exchange as a result of closure of the VDAC. Altered mitochondrial
metabolism is thought to result in an increased negative charge across the mitochondrial
inner membrane. Consequently, this increased stress leads to an influx ofwater to the
matrix followed by rupturing of the outer membrane and subsequent cytochrome c
release from the mitochondria.
The Bcl-2 family of proteins is also thought to regulate the release of cytochrome c
during apoptosis (parone, P.A., et al., 2002; Zomig, M., et al., 2001; Bossy-Wetzel, E., et
aI., 1999). Pro-apoptotic Bcl-2 family members have been shown to induce release of
cytochrome c from mitochondria, whereas anti-apoptotic Bcl-2 proteins prevent it.
However, the precise biochemical mechanism for the regulation of cytochrome c release
by the Bcl-2 family remains to be elucidated. Currently, three models have been
proposed. Firstly, it has been suggested that Bcl-2 family members can form cytochrome
c conducting channels. Studies have shown that Bax and Bak can insert into
mitochondrial membranes and form oligomers or aggregates large enough to allow the
passage of cytochrome c into the cytosol. This has been supported by an electron
microscopy study that showed in vivo Bax and Bak coalesce in large aggregates on the
surface of apoptotic mitochondria. It has also been suggested that Bax and tBid (caspase-
8 cleaved form ofBid) can form large pores on the planar lipid bilayer or could form a
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protein-lipid complex, which might be large enough to allow the passive release of
cytochrome c to the cytosol. In such cases, it has been postulated that Bcl-2 proteins
could prevent the release of cytochrome c by interfering with the formation ofBax or
Bak pores. Another hypothesis for cytochrome c release suggests that pro-apoptotic Bcl-2
proteins, such as Bax, can cause the opening of large channels in the outer mitochondrial
membrane. Studies have shown that pro-apoptotic Bcl-2 family proteins interact with the
outer mitochondrial membrane channel, VDAC, and in doing so form a pore large
enough for the release of cytochrome c. Conversely, anti-apoptotic Bcl-2 family members
have been shown to inhibit the release of cytochrome c by preventing the opening of the
VDAC/Bax pore. Finally, it has been postulated that Bcl-2 family members can control
the release of cytochrome c by regulating the activity of the PTP. For example, Bax/Bak
have been shown to open the PTP. Following opening of the PTP, water and solutes enter
into the mitochondria. Consequently, the mitochondria swells and the outer membrane
ruptures, allowing the passive release of cytochrome c and other apoptogenic factors.
This theory has been supported by several studies which have shown that opening of the
PTP results in the release of cytochrome c and apoptosis, both events beining inhibited by
pharmacological inhibitors of the PTP.
In summary, there are several hypotheses being advanced to explain the mechanism
behind the release of cytochrome c during apoptosis. However, further work is necessary
to elucidate the exact mechanism of cytochrome c release during apoptosis.
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1.7.3 BcI-2
Bel-2 was first identified as an oncogene that was overexpressed in approximately
80% of patients with human follicular B-celllymphoma because of a t(14;18)
chromosomal translocation (Z6rnig, M., et aI., 2001; Graham, S.H., et aI., 2000; Strasser,
A., et aI., 1997). The translocation moves Bel-2 from its normal position at 18q21 into
the immunoglobulin heavy chain locus at 14q3, resulting in transcriptional dysregulation
of the Bel-2 gene and overexpression of the Bel-2 protein. Functional studies of the
effects of deregulated Bel-2 on cultured lymphocytes indicated that Bel-2 rendered
lymphocytes resistant to apoptosis. Since then, it has been well established that
overexpression ofBel-2 can suppress apoptosis in response to a variety of stimuli,
ineluding serum and growth factor deprivation, glucocorticoids, radiation and
chemotherapeutic agents.
In recent years, a rapidly expanding group of genes, structurally or functionally
related to Bc1-2 has been discovered (Graham, S.H., et aI., 2000; Tsujimoto, Y., et aI.,
2000; Strasser, A., et aI., 1997). Based on their biological function and sequence
homology, these proteins are divided into three categories: (1) death-suppressor Bc1-2
family members that contain all of the conseved Bel-2 homology (BH) regions (BHl,
BID, BH3 and BH4) such as Bel-2, Bel-XL, Bel-w, Mel-I, Al (Bft-l) and Boo; (2)
death-promoter Bc1-2 family members that contain BHl, BID and BH3 domains but not
the BH4 domain, such as Bax, Bak, Bad, Mtd (Bok), and Diva; (3) death-promoter Bel-2
family members that contain only the BH3 domain, such as Bik, Bid, Bill, Hrk (Dp5),
Blk and Bnip3, and Bnip3L.
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The Bcl-2 gene family is a key regulator of the apoptotic pathway involving the
mitochondria and cytochrome c (Liu, D., etal., 2001; Graham, S.H., etal., 2000;
Tsujimoto, Y., et aI., 2000; Strasser, A., et aI., 1997). By controlling the release of
mitochondrial apoptogenic factors such as cytochrome c, members of the Bcl-2 family
can either suppress or activate apoptosis. Anti-apoptotic Bcl-2 family members are
located at the outer mitochondrial membrane and act to promote cell survival by
preventing the release of cytochrome c from the mitochondria. On the other hand, pro-
apoptotic Bcl-2 family members are expressed and translocated to the mitochondria in
response to various death signals, resulting in the release of cytochrome c from the
mitochondria into the cytoso1. Once in the cytosol, cytochrome c then binds to Apaf-l in
the presence of dATP. This activated complex then may produce activated caspase-9,
which in tum may cleave downstream caspases such as caspase -3, -6 and -7, which are
central executioners of the apoptotic pathway (Hengartner, M.O., 2000).
The exact mechanism by which Bcl-2 family members induce mitochondrial
dysfunction and release of cytochrome c is controversial (parone, P.A., et aI., 2002; Liu,
D., etal., 2001; Zomig, M., etal., 2001; Tsujimoto, Y., etal., 2000; Bossy-Wetzel, E., et
aI., 1999). Homo- and heterotypic dimmers observed among members of the Bcl-2
family are thought to playa key role. Through heterodimerization, anti-apoptotic and pro-
apoptotic Bcl-2 family members can inhibit or neutralize the biological activity of their
opposing partners. Hence, the relative ratio of these proteins and the different
combinations of their complexes can determine the fate of a cell. In addition to the
regulation of each other's activity through heterodimerization, some Bcl-2 protein
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members can also function independently as observed in transgenic and knockout mice
experiments. As discussed in section 1.7.2., some pro-apoptotic Bc1-2 family members
such as Bad, Bak, Bax and Bid have been proposed to form pores or channels in the outer
mitochondrial membrane through which cytochrome c can diffuse. Other models suggest
that these proteins affect channels in the inner or outer mitochondrial membrane, such as
the PTP, thereby inducing hyperpolarization and permeability transition. Both of these
events have been proposed to cause the entry ofwater and solutes, matrix swelling, and
rupture of the outer membrane, thus allowing the passive release of cytochrome c.
In summary, the Bc1-2 family consists of positive and negative regulators of the
apoptotic pathway. Anti-apoptotic and pro-apoptotic members heterodimerize to suppress
the activity of their partners and also function independently to directly regulate the
release of mitochondrial apoptogenic factors, such as cytochome c. Thus, elucidating the
structure-function and detailed mechanisms of the Bc1-2 family is important for
understanding some of the fundamental principles underlying the apoptotic pathway.
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CHAPTER 2: RESEARCH OBJECTIVES
Breast cancer is the most frequent malignancy among women worldwide, and its
incidence is rising (Arver, B., et aI., 2000). Although there are numerous treatment
modalities currently available, new therapeutic approaches are needed, as age-adjusted
mortality has not changed significantly for fifty years (Wingo, P.A., et aI., 1995).
Utilization of apoptotic pathways is one potential approach.
Apoptosis is an active form of cell death that occurs in most multicellular organisms
and is necessary for numerous fundamental life processes. Apoptosis also occurs in tumor
cells treated with a variety of chemotherapeutic agents. The ability of these agents to
induce apoptosis in tumor cells has now become a rationale for therapeutic approaches
and entertains the possibility that apoptosis may be enhanced in tumors for therapeutic
benefit.
Taxol is one of the most promising agents used for the clinical treatment of breast
cancer (Rowinsky, E.K., et aI., 1995; Holmes, F.A., et aI., 1991). It is known for its
unique ability to stabilize microtubules, thus preventing the completion of mitosis.
Studies have also shown that taxol exerts its cytotoxic effects via the induction of
apoptosis (Kaufmann, S.H., et aI., 2000; Fan, W., 1999; McCloskey, D.E., et aI., 1996;
Bhalla, K., et aI., 1993). The first objective of this project was to assess taxol-induced
apoptosis in MCF-7 and MDA-MB-231 human breast adenocarcinoma cells. Increased
understanding oftaxol-induced apoptosis may lead to the development of more effective
taxol-based chemotherapy regimens and improved clinical responses.
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Currently, the number of techniques designed to identify, quantitate and
characterize apoptosis is escalating as we learn more about the complex mechanisms,
which underlie this process. There is no single feature that can discriminate between cell
death that occurs via apoptosis or necrosis. Furthermore, it is important to note that not
every cell type will display all of the classic features of apoptosis. Therefore, studies
designed to measure multiple aspects of apoptosis must be conducted in order to confirm
the mechanism ofcell death as being either apoptotic or necrotic. For this reason, we
chose three major techniques: morphological assessment, PARP cleavage and TUNEL
assay, which measure different aspects or stages of apoptosis to assess taxol-induced
apoptosis in MCF-7 and MDA-MB-231 cells.
Additionally, many studies have indicated that apoptosis is regulated through
numerous cellular genes, including inducers (p53, Bax, Bcl-xs, Bad, Bak and Bik) and
inhibitors (Bel-2, Bel-XL, Mcl-l) of apoptosis. (Tudor, G., et aI., 2000). Consequently, it
has been hypothesized that defects in apoptosis-regulating genes may cause human
cancers (Thompson, C.B., 1995; Williams, G.T., 1991). Thus, the second objective of our
study was to elucidate the role of the expression of apoptosis regulating genes in taxol-
induced apoptosis using western blot analysis. This would be expected to reveal more
details about mechanisms oftaxol-induced apoptosis in human breast adenocarcinomas.
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CHAPTER 3: MATERIALS AND METHODS
3.1 Materials
Dulbecco's modified Eagle's medium (DMEM) and Ix trypsin-ethylenediamine
tetraacetic acid (EDTA) was purchased from Sigma-Aldrich Canada Ltd. Hyclone was
the supplier of the fetal bovine serum (FBS) and penicillin/streptomycin. MCF-7 and
MDA-MB-23I cells were kindly provided by Dr. Alan Pater, Division ofBasic Medical
Sciences, Faculty ofMedicine, Memorial University ofNewfoundland.
Taxol was purchased from Shanghai Fudan Taxusal New Technology Corporation,
whereas 3-(4,5,-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) and
dimethyl sulfoxide (DMSO) were obtained from Sigma-Aldrich Canada Ltd.
VWR supplied the 0.20 /lm Corning® syringe filters, 6- and 96-well cell culture plates
and 8-well Lab-Tek chamber slides. Sigma-Aldrich Canada Ltd., Vector Laboratories
Inc. and Roche Diagnostics provided the Hoechst 33342 dye, VectaShield mounting
medium, and the In Situ Cell Death Detection Kit, tetra-methyl rhodamine (TMR) red,
respectively.
Sodium azide, hydrochloric acid, methanol, potassium chloride, sodium chloride,
sodium phosphate, potassium phosphate and glycine were purchased from Fisher
Scientific. Furthermore, Sigma-Aldrich Canada Ltd. was the supplier of the Trizma®
base, sodium dodecyl sulfate (SDS), DL-dithiothreitol (DTT), phenylmethylsulfonyl
fluoride (PMSF), aprotinin, igepal CA-630 and sodium deoxycholate.
Bio-Rad Laboratories Ltd. supplied the DC Protein Assay kit, bovine serum
albumin (BSA) standard, ammonium persulfate (APS), acrylamide/bis 29: 1 premixed
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powder and N, N, N', N'-tetramethylethylenediamine (TEMED). Bromophenol blue,
Ponceau S and mouse anti-p-actin monoclonal antibody (mAb) were purchased from
Sigma. BD PharMingen supplied purified mouse anti-human mAbs for PARP and
cytochrome c. Novocastra Laboratories and Santa Cruz Biotechnology Inc. supplied the
mouse anti-human mAbs for p53 and Bcl-2, respectively. Enhanced chemilumiscence
(ECLTM) horseradish peroxidase-conjugated anti-mouse immunoglobulin G (IgG)
antibody, ECLTM detection system, Hyperfilm™ ECLTM nitrocellulose membrane,
Hyperfilm™ ECLTM and the electrode paper were purchased from Amersham
Biosciences. Invitrogen Canada Inc. and Carnation were the suppliers of the
BenchMark™ Prestained protein ladder and skim milk powder, respectively.
3.2 Methods
3.2.1 Cell Culture
MCF-7 and MDA-MB-231 cells are human breast adenocarcinoma cell lines
derived from the pleural effusion ofwomen with metastatic breast cancer (Cailleau, R., et
a/., 1974; Soule, H.D., etal., 1973). Both MCF-7 andMDA-MB-231 were maintained as
a monolayer inDMEM supplemented with 10% FBS and 1% penicillin/streptomycin.
They were routinely cultured in 75 cm2 flasks at 37°C in a humidified incubator with an
atmosphere of 5% CO2.
During subculturing, once the cells reached subconfluence, the medium was
removed from the flasks and the monolayers were washed with approximately 10 mL of
phosphate-buffered saline (pBS, pH 7.4) (2.67 mM KCI, 1.47 mM KH2P04, 138 mM
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NaCI, 8.10 roM Na2HP04-7H20). Cells were left in PBS for at least 30 seconds to
remove as much of the extracellular protein as possible. The PBS was then removed and
3 mL of Ix trypsin-EDTA solution (which had been pre-warmed to 37°C) was added.
The flasks were placed back in the 37°C humidified incubator for approximately 2-3
minutes and were then checked under an inverted light microscope to ensure that the cell
monolayers were lifting off the flasks. Once the majority of cells had detached from the
flasks, approximately 8 mL ofPBS was added to each flask and the cell suspensions were
transferred to a sterile 15 mL conical centrifuge tube. The cells were then spun down at
1200 rpm for 5 minutes using a Thermo IEC tabletop centrifuge. Following
centrifugation, the supernatants were carefully removed using sterile, disposable 10 mL
pipettes. The cell pellets were then resuspended with DMEM and were subsequently
reseeded at a 1:3 or 1:4, or were counted with a hemocytometer in order to achieve
specific concentrations of cells.
Cells were maintained in the logarithmic phase of growth at the time of drug
treatment throughout all experimental assays.
3.2.2 Preparation of Taxol Working Solutions
One hundred JlM and 10,000 JlM stock solutions oftaxol were prepared in DMSO
and were sterilized using a 0.20 Jlm Corning® syringe filter. The stock solutions were
then aliquotted aseptically into autoc1aved 1.5 mL Eppendorftubes and were stored at
-20°C. Immediately prior to an experiment, working solutions were prepared by diluting
taxol stock solutions in DMEM to the appropriate concentration. At no time throughout
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the experimental assays did the final DMSO concentration in the taxol working solutions
exceed 0.1%.
3.2.3 Assessment of Cytotoxicity
3.2.3.1 Assessment of Cytotoxicity ofDMSO in MCF-7 and MDA-MB-231 Cells
Since taxol solutions were prepared in DMSO, it was essential to demonstrate that
the amount ofDMSO used was not toxic and all cell death observed with taxol solutions
was attributed to taxol alone. The cytotoxicity ofDMSO in MCF-7 and MDA-MB-231
cells was assessed using the MTT assay. This assay is based on the reduction of a
tetrazolium salt, MTT, to a colored formazen product by mitochondrial dehydrogenase
present only in living, metabolically active cells (Sladowski, D., et aI., 1993; Mosmann,
T., 1983). In brief, 2 x 104 cells/100 fJ.L/ well were seeded in eight replicates into 96-well
microtitre plates and were incubated for 24 hours at 37°C in a 5% C02 humidified
incubator to allow adherence of cells. The medium was then removed and medium
containing 0.5%,1.0%,1.5% and 2.0% DMSO was added to the wells. The plates were
returned to the incubator for 72 hours. Cells containing no DMSO were also cultured
under the same conditions as control.
After 72 hours, 100 fJ.L of a 5 mgjmL solution ofMTT in PBS was added to each
well. The MTT solution had been filtered using a sterile 0.20 fJ.m Corning® syringe filter
to remove any insoluble residue that may be present in some batches ofMTT. Following
4 hours of incubation with MTT at 37°C, the supernatant was carefully removed and 100
fJ.L ofDMSO was added to each well to solubilize any formazan crystals generated. The
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plates were then agitated on a plate shaker for 20 minutes at room temperature to ensure
that all the crystals had been dissolved. The plates were then read on a Bio-Rad Model
550 microplate reader interfaced with an EM PaC 386 computer, using a test wavelength
of 570 nm and a reference wavelength of 630 nm. The reference wavelength was used in
order to detect any artifacts in the plates and was subtracted from the 570 nm values.
Data analysis was carried out using the Bio-Rad Microplate Manager®/ PC version 4
software program. Percentage of cell survival was expressed as:
mean absorbance for each DMSO concentration x 100%
mean control absorbance
Percentage of cell survival was then plotted versus percentage ofDMSO.
Experiments were repeated at least three times and the results were expressed as mean +/-
standard deviation (SD).
3.2.3.2 Assessment of Cytotoxicity of Taxol in MCF-7 and MDA-MB-231 Cells
The MTT assay was also used to assess the cytotoxicity oftaxol in MCF-7 and
MDA-MB-231 cells. Taxol solutions (6.4 x 10-4 /lM, 3.2 x 10-3 /lM, 1.6 x 10-2 /lM, 0.08
11M, 0.4 /lM, 2 /lM and 10 /lM) were prepared from a stock solution (10,000 /lM) that
had been further diluted in DMSO and subsequently in DMEM, such that the final
DMSO concentration was 0.01% or less. In brief, 2 x 104 cellsllOO /lL/ well were seeded
in eight replicates into a 96-well microtitre plate and were incubated for 24 hours at 37°C
in a 5% CO2 humidified incubator to allow adherence of cells. The medium was then
removed and taxol solutions (6.4 x 10-4 /lM, 3.2 x 10-3 /lM, 1.6 x 10-2 /lM, 0.08 /lM, 0.4
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~M, 2 ~M and 10 ~M) were added to the wells. The cells were returned to the incubator
for 72 hours. Cells containing no taxol were also cultured under the same conditions as
control.
After 72 hours, 100 ~L ofa 5 mg/mL solution ofMTT in PBS was added to each
well. Following 4 hours of incubation with MTT at 37°C, the supernatant was carefully
removed and 100 ~L ofDMSO was added to each well to solubilize any formazan
crystals generated. The plates were agitated on a plate shaker for 20 minutes at room
temperature to ensure that all the crystals had been dissolved. The plates were then read
on a Bio-Rad Model 550 microplate reader interfaced with an EM PaC 386 computer,
using a test wavelength of 570 nm and a reference wavelength of 630 nm. The reference
wavelength was used in order to detect any artifacts in the plates and was subtracted from
the 570 nm values. Data analysis was carried out using the Bio-Rad Microplate
Manager®/ PC version 4 software program. Percentage of cell survival was expressed as:
mean absorbance for each taxol concentration x 100%
mean control absorbance
Percentage of cell survival was then plotted versus taxol concentration. The taxol
concentration causing 50% inhibition of cell growth (ICso) was determined from the
curve. Experiments were repeated at least three times and the results were expressed as
mean +/- SD.
50
3.2.4 Morphological Examination
Apoptosis is characterized by a distinct set of morphological features. In order to
assess whether MCF-7 and MDA-MB-231 cells exhibit these features upon exposure to
100 nM taxol for 3, 8, 24, 48 and 72 hours, cells were examined using light and
fluorescence microscopy.
One hundred thousand cells per 400 J,!L/well were seeded in triplicate into 8-well
Lab-Tek chamber slides and were incubated for 24 hours at 37° C in a 5% CO2
humidified incubator to allow adherence of cells. After 24 hours in culture, the medium
was replaced and medium containing 100 nM taxol was added to the culture. The cells
were incubated for 3, 8,24,48 and 72 hours, respectively. Cells containing no taxol were
assessed under the same conditions as control.
3.2.4.1 Evaluation of Apoptotic Morphology by Light Microscopy
Morphological changes were assessed using differential interference contrast (DIC)
microscopy. Following 3, 8,24,48 and 72 hours exposure to 100 nM taxol, the gasket
and chamber frame of the 8-well Lab-Tek chamber slides were removed, and cells were
coverslipped, examined and photographed at 20 X magnification using an Olympus X WI
microscope with Spot RT Slider Digital camera. Cells containing no taxol were also
assessed under the same conditions as control. Experiments were repeated at least three
times to ensure that all pictures obtained were representative of the conditions.
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3.2.4.2 Analysis of Chromatin Condensation By Fluorescence Microscopy
Chromatin condensation, one of the hallmarks of apoptosis, was examined using
Hoechst staining. Following 3,8,24,48 and 72 hours exposure to 100 nM taxol, the
chamber frame of the 8-well Lab-Tek chamber slides were removed and individual wells
of the slides were washed in approximately 400 ilL ofPBS. The PBS was then removed
and cells were fixed in ice-cold methanol (400 ilL/well) for 10 minutes at room
temperature. The slides were then washed three times (5 minutes per wash) by placing
slides in coplin jars filled with PBS and were then stained for 10 minutes with 200
ilL/well of 0.5 Ilg/mL Hoechst 33342 in PBS. The slides were then washed again three
times with PBS (5 minutes per wash) and were mounted with 90% glycerol for MDA-
MB-231 and VectaShield mounting medium for MCF-7. The cells were then
coverslipped, examined and photographed at 40 X magnification using an Olympus BX
50 microscope at an excitation wavelength of360-730 nm and an emission wavelength of
460 nm. The Hoechst dye stains morphologically normal nuclei dimly blue, whereas
apoptotic nuclei demonstrate condensed, smaller and very intensely bright blue nuclei
(Eguchi, Y., etal., 1997).
Cells containing no taxol were assessed under the same conditions as control.
Experiments were repeated at least three times to ensure that all photographs obtained
were representative of the conditions.
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3.2.5 TUNEL Assay
Degradation of chromosomal DNA into nucleosome-sized fragments is one of the
characteristics of apoptotic cell death. To assess whether MCF-7 and MDA-MB-231 cells
exhibit this feature upon exposure to 100 nM taxol, the In Situ Cell Death Detection kit,
TMR red, utilizing TUNEL technology was employed.
One hundred thousand cells per 400 ilL/well were seeded in triplicate into 8-well
Lab-Tek chamber slides and were incubated at 37° C in a 5% CO2 humidified incubator
for 24 hours to allow adherence of cells. After 24 hours in culture, the medium was
replaced and medium containing 100 nM taxol was added to the culture for 3, 8, 24, 48
and 72 hours, respectively. Cells containing no taxol were assessed under the same
conditions as control.
Following 3, 8,24,48, and 72 hours exposure to 100 nM taxol, the gasket and
chamber frame of the 8-well Lab-Tek chamber slides were removed and individual wells
of the slides were washed in approximately 400 ilL ofPBS. The PBS was then removed
and cells were fixed in 1: 1 acetone:methanol (400 ilL/well) for 10 minutes at -20°C. The
slides were then washed again three times (5 minutes per wash) by placing slides in
coplin jars filled with PBS and were then stained in 75 ilL/well ofTUNEL reaction
mixture (containing terminal deoxynucleotidyl transferase and TMR-Iabeled dUTP) for 1
hour at 37° C in a 5% CO2 humidified incubator. Following staining, the cells were then
washed again three times (5 minutes per wash) by placing slides in coplin jars filled with
PBS and slides were mounted in VectaShield mounting medium. The cells were then
coverslipped, examined and photographed at 40 X magnification using an Olympus BX
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50 microscope at an excitation wavelength of 530-550 nm and an emission wavelength of
570-620 nm. Apoptotic cells were easily identified as they were stained bright red. The
number of apoptotic cells out of 300 randomly selected cells was then determined in each
of the triplicate wells and the results were expressed as mean +/- SD. Experiments were
repeated at least three times to ensure that all results obtained were representative of the
conditions.
3.2.6 Extraction of Protein from MCF-7 and MDA-MB-231 Cells
Protein from MCF-7 and MDA-MB-231 was extracted according to a published
method (Yang, X., et al., 1998). Briefly, 1 x 106 cells/2 mL were seeded into 6-well
plates and were grown to 80-85% confluency. Once cells reached this confluency level,
the medium was replaced with medium containing 100 nM taxo!' After 3,8,24,48, and
72 hours, taxol present in the cell culture was removed by aspiration of the medium and
the cells were washed twice with approximately 2-3 mL of ice-cold PBS. Then, 250 JlL
of ice-cold lysis buffer [50 mM Tris-HCI, pH 8.0; 150 mM NaCI; 0.02% sodium azide;
igepal CA-630; 0.1% SDS; 0.5% sodium deoxycholate; dH20; PMSF dissolved in 100%
ethanol (10 mg/ml), and aprotinin dissolved in dH20 (2 mg/mL)] was added to each well.
The lysated cells were then scraped using a Costar® cell scraper, transferred into an ice
chilled 1.5 mL Eppendorf tube, and kept on ice for 30 minutes. Following this, the
mixture was centrifuged using an IEC MicoMax centrifuge at 12,000 g at 4°C for 10
minutes. The supernatant was then collected and aliquotted out into portions of 50 JlL/l.5
mL Eppendorf tubes. The lysate was then stored at -80°C until protein quantification .
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using the Bio-Rad DC Protein assay kit was performed. Cells containing no taxol were
assessed under the same conditions as control.
3.2.7 Bio-Rad DC Protein Assay
To determine protein concentration, the Bio-Rad DC protein assay was performed
using a commercially available kit, according to manufacturer's instructions. This
colorimetric assay allows determination of protein concentration following detergent
solubilization and is based on the reaction of protein with an alkaline copper tartrate
solution and folin reagent (peterson, G.L., 1979; Lowry, O. H., et aI., 1951). As with the
Lowry assay, there are two steps that lead to color development: the reaction between
protein and copper in an alkaline medium, and the subsequent reduction of folin regent
by the copper-treated protein.
Prior to the determination of protein content in the extracts, a standard curve was
generated using BSA as the standard. For optimal results, the BSA solutions were
prepared in the same lysis buffer [50 roM Tris-HCL, pH 8.0; 150 mM NaCI; 0.02%
sodium azide; igepal CA-630; 0.1% SDS; 0.5% sodium deoxycholate; dH20; PMSF
dissolved in ethanol (IOmg/ml); and aprotinin dissolved in dH20 (2 mg/mL)] as that of
the samples. At that time, the working reagent (A') was also prepared. Because the
samples contained detergent, the working reagent (A') was prepared by adding 40 JlL of
reagent S (surfactant) to 2 mL of reagent A (alkaline copper tartrate solution). This is
done in order to make the assay more detergent compatible.
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Once the working reagent (A') and BSA standard solutions were prepared, 5 ilL of
standards and samples were pipetted into a clean, dry 96-well microtitre plate. Each
standard and sample was prepared in triplicate. Next, 25 ilL of reagent A', followed by
200 ilL of reagent B (folin reagent) was added to each well. The plates were then agitated
gently and were left to sit for 15 minutes to allow color development. During this time,
any bubbles that may have formed during pipetting and agitation were popped using a
clean, dry pipet tip, as they can interfere with absorbance readings. The plates were read
on a Bio-Rad Model 550 microplate reader interfaced with an EM PaC 386 computer,
using a test wavelength of630 nm. Data analysis was then carried out using the Bio-Rad
Microplate Manager®/ PC version 4 software program at which time the protein
concentration was determined.
3.2.8 Western Blot
To elucidate the role of apoptotic regulatory proteins in taxol-induced apoptosis in
MCF-7 and MDA-MB-231 cells, western blot analysis was performed. Briefly, MCF-7
and MDA-MB-231 cells were exposed to 100 nM taxol and protein extracts were
prepared as described in Section 3.2.6. The protein extracts were then resolved in a
discontinuous polyacrylamide gel consisting of a resolving or separating (lower) gel and
a stacking (upper) gel. The stacking gel served to concentrate large sample volumes,
resulting in better band resolution, whereas the resolving gel separated the molecules.
The resolving gel was prepared with 10-15% acrylamide; 375 mM TrisIHCL, pH 8.8;
0.1% SDS; 0.1% APS and 41lL ofTEMED. The stacking gel was composed of5%
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acrylamide; 125 mMTrislHCL, pH 6.8; 0.1% SDS, 0.1% APS and 5IlLofTEMED.
While the stacking gel was polymerizing, the protein extracts, ranging from 5-60 Ilg,
were boiled in 2x SDS-polyacrylamide gel electrophoresis (PAGE) gel loading buffer
(0.125 M TrisIHCL, pH 6.8; 4% SDS; 0.3 mM bromophenol blue; 20% glycerol and 0.2
mM DTT) or 6x SDS-PAGE gel loading buffer (0.35 M TrisIHCL, pH 6.8; 10% SDS;
0.175 mM bromophenol blue; 30% glycerol; and 0.6 M DTT) for 4 minutes. The protein
extracts were then loaded into the sample wells and electrophoresis was conducted at
200V in SDS-PAGE running buffer (24.6 mM Tris, 191 mM Glycine, 3.46 mM SDS)
using the Mini-Protean® II apparatus (Bio-Rad Laboratories, Ltd.).
Following electrophoresis, the Mini-Protean® II apparatus (Bio-Rad) was
dismantled and the gel was equilibrated in transfer buffer (25 mM Tris, 192 mM Glycine,
20% methanol) for 30 minutes. Equilibration facilitates the removal of electrophoresis
buffer salts and detergents, which is necessary to prevent an increase in the conductivity
of the transfer buffer. During the 30-minute equilibration period, the transfer buffer was
changed every 10 minutes in order to prevent the diffusion of low molecular weight
proteins. Also during this time, the Hybond™ ECLTM Nitrocellulose membrane
(Amersham Biosciences) was soaked in transfer buffer for 15-30 minutes. Once the
equilibration was completed, the transfer sandwich (consisting of filter paper, membrane,
gel and fiber pads) was assembled into the transfer cassette and placed in a buffer tank
containing transfer buffer. Subsequently, the proteins were transferred to the Hybond™
ECLTM Nitrocellulose membrane at 100V for 90 minutes using the Mini Trans-Blot®
apparatus (Bio-Rad Laboratories, Ltd.). To ensure transfer was successful, the membrane
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was stained with Ponceau S Staining solution (0.5% (w/v) Ponceau S, 1 % (v/v) glacial
acetic acid) for approximately 30 seconds and destained in distilled water until bands
were visible.
Following this, non-specific binding sites were blocked by immersing the
membrane in 5% skim milk powder in TBST (20 mM Tris/HCL, 137 mM NaCI, 0.1%
Tween-20) for 1 hour at room temperature on a shaker. Subsequently, the membrane was
incubated with the primary antibody (purified mouse anti-human mAbs for PARP,
cytochrome c, p53 or Bc1-2) diluted in 5 % skim milk powder in TBST overnight at room
temperature with shaking. After briefly rinsing the membrane using two changes of
TBST and then washing once for 15 minutes and twice for 5 minutes, the membrane was
incubated with horseradish peroxidase-conjugated anti-mouse secondary antibody diluted
1: 1500 in 5% skim milk powder and TBST for 1 hour at room temperature. The
membrane was then washed as previously described and signals were detected using the
ECLTM system (Amersham Biosciences). To do this, the membrane was incubated in
equal volumes of detection reagent 1 and detection reagent 2 for exactly 1 minute. Excess
detection reagent was then drained off and the membrane was exposed to Hyperfilm™
ECLTM, as instructed by the manufacturer.
In order to ensure that any observed changes in protein expression was not due to
differences in the amount of protein loaded, the membrane was stripped of the primary
signal and reprobed with anti-~-actin mAb. To do this, the membrane was incubated in
stripping buffer (100 mM 2-mercaptoethanol; 2 % SDS; 62.5 mM Tris/HCL, pH 6.8) at
50°C for 15-30 minutes with occasional agitation. The membrane was then washed twice
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with TBST for 10 minutes at room temperature and was then blocked in 7% skim milk
powder in TBST for 2 hours at room temperature. Subsequently, the membrane was
incubated with anti-p-actin mAb diluted 1:10,000 in 5% skim milk powder and TBST
overnight at room temperature on a shaker. The signals were then detected as described
for the primary signal. In some cases, the membrane was stored wet and wrapped in
plastic at 4°C after each immunodetection. These membranes were then reprobed at a
later date.
The resulting immunoblot signals were quantified by densitometry using the
chemiImager 4000 software program. The densitometric value for each of the p-actin
bands corresponding to 3, 8,24,48 and 72 hours was divided into the value of the p-actin
band at 0 hours. The resulting ratios were then multiplied by the corresponding
densitometric value for the cytochrome c, p53, or Bc1-2 bands in order to normalize to
the p-actin control. Protein levels were then expressed as cytochrome c, p53, or Bc1-2/ p-
actin optical density (O.D.) ratio. Experiments were repeated at least three times and the
values were represented as the mean +/- SD.
3.2.9 Statistical Analysis
Statistical analysis was conducted using the student's t-test in the SigmaPlot® 8.0
software program. Differences with a value of*, p<0.05 were considered to be
statistically significant, while those with a value of **, p<O.OOl were considered
statistically very significant.
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CHAPTER 4: RESULTS
4.1 Cytotoxicity of DMSO and Taxol in MCF-7 and MDA-MB-231 Cells
Cytotoxicity studies ofDMSO and taxol in MCF-7 and MDA-MB-231 cells were
conducted using the colorimetric MTT assay. Because taxol solutions were prepared in
DMSO, it was imperative that the percentage ofDMSO used to dissolve taxol was not
toxic and all cell death observed was attributed to taxol alone. Hence, we initially
examined the cytotoxicity of 0.5%, 1.0%, 1.5% and 2.0% DMSO in these cell lines. As
shown in Figure 4.1 and Figure 4.2, the percentage of cell survival in both cell lines
decreased dose-dependently in response to the varying concentrations ofDMSO.
Furthermore, 0.5% DMSO was observed to have little antiproliferative effect on both cell
lines. Based on these observations and those in the literature, stock solutions of taxol
were made in DMSO, so that the highest concentration ofDMSO used for cell treatment
was 0.1% or less (Tudor, G., et aI., 2000).
Cytotoxicity oftaxol in MCF-7 and MDA-MB-231 cells was also evaluated by the
MTT assay. Both cell lines were incubated in medium containing 5-fold serial dilutions
oftaxol (6.4 x 10·4IlM-10 IlM) for 72 hours. Figure 4.3 and Figure 4.4 show
representative graphs of cell survival percentages for MCF-7 and MDA-MB-231 cells
treated with varying concentrations of taxol for 72 hours. The ICso or concentration of
taxol causing 50% growth inhibition was generated from these graphs. The ICso values
for MCF-7 and MDA-MB-231 cells were 0.040 IlM and 0.013 IlM, respectively (Table
4.1). These results suggest an increased sensitivity ofMDA-MB-231 cells to taxol vs.
MCF-7 cells.
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By comparison, our ICso values are different with that of a similar study with MCF-
7 and MDA-MB-231 cells treated with taxol, where they reported an ICso value of
0.0047JlM in both cell lines (Beech, D.l, et aI., 2001). However, these differences may
reflect the use of different methodologies and exposure times to taxo!.
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Figure 4.1. Cytotoxicity ofDMSO in MCF-7 Cells
2.00%
A 3-day MTT colorimetric assay was used to determine the cytotoxicity of 0.5%, 1.0%,
1.5% and 2.0% DMSO in MCF-7 cells, as described in Materials and Methods.
Percentage of cell survival was plotted against the concentration ofDMSO. Each point
represents the mean from at least three independent experiments +/- SD.
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Figure 4.2. Cytotoxicity of DMSO in MDA-MB-231 Cells
A 3-day MTT colorimetric assay was used to determine the cytotoxicity of 0.5%, 1.0%,
1.5% and 2.0% DMSO in MDA-MB-231 cells, as described in Materials and Methods.
Percentage of cell survival was plotted against the concentration ofDMSO. Each point
represents the mean from at least three independent experiments +/- SD.
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Figure 4.3. Cytotoxicity of Taxol in MCF-7 Cells
A 3-day MTT colorimetric assay was used to determine the cytotoxicity oftaxol in MCF-
7 cells, as described in Materials and Methods. Percentage of cell survival was plotted
against the concentration of taxo!. Each point represents the mean from at least three
independent experiments +/- SD.
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Figure 4.4. Cytotoxicity of Taxol in MDA-MB-231 Cells
A 3-day MTT colorimetric assay was used to determine the cytotoxicity oftaxol in
MDA-MB-231 cells, as described in Materials and Methods. Percentage of cell survival
was plotted against the concentration of taxo!. Each point represents the mean from at
least three independent experiments +/- SD.
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Table 4.1. ICso Values of Taxol in MCF-7 and MDA-MB-231 Cells
A 3-day MTT colorimetric assay was used to determine the cytotoxicity oftaxol in MCF-
7 and MDA-MB-231 cells, as described in Materials and Methods. Percentage of cell
survival was plotted against the concentration of taxo!. From this, the ICso or
concentration oftaxol causing 50% growth inhibition was calculated.
Cells
MCF-7
MDA-MB-231
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ICso (11M)
0.040
0.013
4.2 Morphological Changes Evaluated by Light Microscopy
Morphological changes often serve as markers of apoptotic cell death (Wen, L-P.,
et aI., 1997). To evaluate whether taxol induces apoptosis in MCF-7 and MDA-MB-231
cells exposed to 100 nM taxol for 3, 8,24,48 and 72 hours, DIC microscopy was
employed. Control cells containing no taxol were also cultured under the same conditions
and represented the 0 hours time point. As shown in Figure 4.5 and Figure 4.6, the most
conspicuous changes observed in taxol-treated cells included cell shrinkage and extensive
detachment of the cells from the cell culture substratum. These changes are characteristic
of apoptotic cell death and became visible after 3 hours treatment with 100 nM taxol.
Other characteristic features of the apoptotic process, such as rounding up of cells,
apoptotic body formation and membrane blebbing were also observed. These
morphological changes became more remarkable with increased exposure time.
Furthermore, these observations suggest that MCF-7 and MDA-MB-231 cells, treated
with 100 nM taxol, detached from the substratum and died by apoptosis. Experiments
were repeated at least three times to ensure that all photographs obtained were
representative of the conditions.
67
68
Figure 4.5. Representative Photomicrographs Demonstrating Morphological
Changes of MCF-7 Cells Undergoing Apoptosis Induced by 100 nM Taxol
Apoptotic morphology was assessed by the use ofDIC microscopy. Following 3, 8, 24,
48, and 72 hours exposure to 100 nM taxol, cells were examined and photographed at 20
X magnification, as described in Materials and Methods. Control cells containing no
taxol were also cultured under the same conditions and represented the 0 hours time
point. Arrows indicate examples of apoptotic cells. These data are representative of at
least three independent experiments.
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Figure 4.5. Representative Photomicrographs Demonstrating Morphological
Changes of MCF-7 Cells Undergoing Apoptosis Induced by 100 oM Taxol
Apoptotic morphology was assessed by the use ofDIC microscopy. Following 3, 8,24,
48, and 72 hours exposure to 100 nM taxol, cells were examined and photographed at 20
X magnification, as described in Materials and Methods. Control cells containing no
taxol were also cultured under the same conditions and represented the 0 hours time
point. Arrows indicate examples of apoptotic cells. These data are representative of at
least three independent experiments.
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Figure 4.5. Representative Photomicrographs Demonstrating Morphological
Changes of MCF-7 Cells Undergoing Apoptosis Induced by 100 nM Taxol
Apoptotic morphology was assessed by the use ofDIC microscopy. Following 3, 8, 24,
48, and 72 hours exposure to 100 nM taxol, cells were examined and photographed at 20
X magnification, as described in Materials and Methods. Control cells containing no
taxol were also cultured under the same conditions and represented the 0 hours time
point. Arrows indicate examples of apoptotic cells. These data are representative of at
least three independent experiments.
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Figure 4.6. Representative Photomicrographs Demonstrating Morphological
Changes in MDA-MB-231 Cells Undergoing Apoptosis Induced by 100 nM Taxol
Apoptotic morphology was assessed by the use ofDIC microscopy. Following 3,8,24,
48, and 72 hours exposure to 100 nM taxol, cells were examined and photographed at 20
X magnification, as described in Materials and Methods. Control cells containing no
taxol were also cultured under the same conditions and represented the 0 hours time
point. Arrows indicate examples of apoptotic cells. These data are representative of at
least three independent experiments.
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Figure 4.6. Representative Photomicrographs Demonstrating Morphological
Changes in MDA-MB-231 Cells Undergoing Apoptosis Induced by 100 nM Taxol
Apoptotic morphology was assessed by the use ofDIC microscopy. Following 3,8,24,
48, and 72 hours exposure to 100 nM taxol, cells were examined and photographed at 20
X magnification, as described in Materials and Methods. Control cells containing no
taxol were also cultured under the same conditions and represented the 0 hours time
point. Arrows indicate examples of apoptotic cells. These data are representative of at
least three independent experiments.
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Figure 4.6. Representative Photomicrographs Demonstrating Morphological
~ .'. .'
Changes in MDA-MB-231 Cells Undergoing Apoptosis Induced by 100 oM Taxol
Apoptotic morphology was assessed by the use ofDIC microscopy. Following 3, 8, 24,
48, and 72 hours exposure to 100 nM taxol, cells were examined and photographed at 20
X magnification, as described in Materials and Methods. Control cells containing no
taxol were also cultured under the same conditions and represented the 0 hours time
point. Arrows indicate examples of apoptotic cells. These data are representative of at
least three independent experiments.
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4.3 Chromatin Condensation Analyzed by Fluorescence Microscopy
Chromatin condensation, one of the hallmarks of apoptosis, was assessed using
Hoechst staining, a dye that stains morphologically normal nuclei dimly blue, whereas
apoptotic nuclei demonstrate condensed, smaller and very intensely bright blue nuclei
(Eguchi, Y., et aI., 1997). To do this, MCF-7 and MDA-MB-231 cells were treated with
100 nM taxol for 3, 8, 24, 48, and 72 hours and stained using Hoechst 33342, as
described in Materials and Methods. Control cells containing no taxol were also cultured
under the same conditions and represented the ahours time point. As shown in Figure 4.7
and Figure 4.8, some differences were observed in the nuclei of 100 nM taxol-treated and
untreated MCF-7 and MDA-MB-231 cells. These differences in nuclear morphology,
initially observed at 8 hours of 100 nM taxol treatment and most apparent at 24 hours,
reflected chromatin condensation and nuclear shrinkage. Experiments were repeated at
least three times to ensure that all photographs obtained were representative of the
conditions.
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Figure 4.7. Representative Fluorescence Photomicrographs of MCF-7 Cells Stained
with Hoechst 33342
Cells were treated with 100 nM taxol for 3, 8,24,48 and 72 hours, stained with Hoechst
33342 and photographed at 40 X magnification, as described in Materials and Methods.
Control cells containing no taxol were also cultured under the same conditions and
represented the 0 hours time point. The Hoechst 33342 dye stains morphologically
normal nuclei dimly blue whereas apoptotic nuclei demonstrate condensed, intensely
bright blue and smaller nuclei. These data are representative of at least three independent
experiments.
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Figure 4.7. Representative Fluorescence Photomicrographs of MCF-7 Cells Stained
with Hoechst 33342
Cells were treated with 100 nM taxol for 3, 8, 24, 48 and 72 hours, stained with Hoechst
33342 and photographed at 40 X magnification, as described in Materials and Methods.
Control cells containing no taxol were also cultured under the same conditions and
represented the 0 hours time point. The Hoechst 33342 dye stains morphologically
normal nuclei dimly blue whereas apoptotic nuclei demonstrate condensed, intensely
bright blue and smaller nuclei. These data are representative of at least three independent
experiments.
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Figure 4.7. Representative Fluorescence Photomicrographs of MCF-7 Cells Stained
with Hoechst 33342
Cells were treated with 100 nM taxol for 3, 8, 24, 48 and 72 hours, stained with Hoechst
33342 and photographed at 40 X magnification, as described in Materials and Methods.
Control cells containing no taxol were also cultured under the same conditions and
represented the 0 hours time point. The Hoechst 33342 dye stains morphologically
normal nuclei dimly blue whereas apoptotic nuclei demonstrate condensed, intensely
bright blue and smaller nuclei. These data are representative of at least three independent
experiments.
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Figure 4.8. Representative Fluorescence Photomicrographs of MDA-MB-231 Cells
Stained with Hoechst 33342
Cells were treated with 100 nM taxol for 3, 8, 24,48 and 72 hours, stained with Hoechst
33342 and photographed at 40 X magnification, as described in Materials and Methods.
Control cells containing no taxol were also cultured under the same conditions and
represented the 0 hours time point. The Hoechst 33342 dye stains morphologically
normal nuclei dimly blue whereas apoptotic nuclei demonstrate condensed, intensely
bright blue and smaller nuclei. These data are representative of three independent
experiments.
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Figure 4.8. Representative Fluorescence Photomicrographs of MDA-MB-231 Cells
Stained with Hoechst 33342
Cells were treated with 100 nM taxol for 3,8,24,48 and 72 hours, stained with Hoechst
33342 and photographed at 40 X magnification, as described in Materials and Methods.
Control cells containing no taxol were also cultured under the same conditions and
represented the 0 hours time point. The Hoechst 33342 dye stains morphologically
normal nuclei dimly blue whereas apoptotic nuclei demonstrate condensed, intensely
bright blue and smaller nuclei. These data are representative of three independent
experiments.
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Figure 4.8. Representative Fluorescence Photomicrographs of MDA-MB-231 Cells
Stained with Hoechst 33342
Cells were treated with 100 nM taxol for 3, 8,24,48 and 72 hours, stained with Hoechst
33342 and photographed at 40 X magnification, as described in Materials and Methods.
Control cells containing no taxol were also cultured under the same conditions and
represented the 0 hours time point. The Hoechst 33342 dye stains morphologically
normal nuclei dimly blue whereas apoptotic nuclei demonstrate condensed, intensely
bright blue and smaller nuclei. These data are representative of three independent
experiments.
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4.4 DNA Fragmentation Assessed by TUNEL say
DNA fragmentation is a common biochemictnallmark of apoptosis (Sikorska, M.,
et al., 1997; Walker, P.R., et aI., 1997). Therefore,' phenomenon provides a strong
indication of apoptotic cell death. To assess the DNfragmentation induced by taxol in
MCF-7 and MDA-MB-231, cells were treated withOO nM taxol for 3,8,24,48, and 72
hours and stained using the TUNEL procedure, as (~ribed in Materials and Methods.
Control cells containing no taxol were also culturedunder the same conditions and
represented the 0 hours time point. Based on the TlffiL assay, MCF-7 and MDA-MB-
231 cells exhibiting DNA strand breaks, a consequ e of apoptosis, will incorporate the
TMR red (fluorochrome) tagged deoxynuc1eotides, hereas non-apoptotic cells will not.
Thus, apoptotic cells are easily identifiable as they 'n intensely bright red. As shown in
the representative photomicrographs in Figure 4.9 a-l Figure 4.10, the incidence of cells
staining positive for DNA strand breaks and hence 'Wg apoptotic, increased with
increasing exposure time to 100 nM taxo!'
The percentage of apoptotic cells was then dennined by counting the number of
apoptotic cells out of300 randomly selected cells fi each condition and the results were
expressed as mean +/- SD. As shown in Figure 4.111lld Figure 4.12, the percentage of
apoptotic cells increased time-dependently in respoJ! to 100 nM taxo!' Furthermore, a
statistically significant (*p<0.05) increase in the perrotage ofapoptotic cells, when
compared to untreated cells, was detected in MDA-l:B-231 and MCF-7 cells treated with
100 nM taxol following 3 and 8 hours exposure, resp.'Ctively. By 24,48 and 72 hours
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treatment with 100 nM taxol, there was a very statistically significant increase
(**p<O.OOl) in the percentage of apoptotic cells vs. control in both cell lines.
Experiments were repeated at least three times to ensure that all photographs obtained
were representative of the conditions.
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Figure 4.9. Representative Fluorescence Photomicrographs of MCF-7 Cells Stained
Using the TUNEL Procedure
Cells were treated with 100 nM taxol for 3, 8, 24,48, and 72 hours, stained using the
TUNEL procedure and photographed at 40 X magnification, as described in Materials
and Methods. Control cells containing no taxol were also cultured under the same
conditions and represented the ahours time point. Apoptotic MCF-7 cells were easily
identifiable as they were stained bright red. These data are representative of at least three
independent experiments.
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Figure 4.9. Representative Fluorescence Photomicrographs of MCF-7 Cells Stained
Using the TUNEL Procedure
Cells were treated with 100 nM taxol for 3, 8, 24,48, and 72 hours, stained using the
TUNEL procedure and photographed at 40 X magnification, as described in Materials
and Methods. Control cells containing no taxol were also cultured under the same
conditions and represented the 0 hours time point. Apoptotic MCF-7 cells were easily
identifiable as they were stained bright red. These data are representative of at least three
independent experiments.
8-Hours
24-Hours
98
99
Figure 4.9. Representative Fluorescence Photomicrographs of MCF-7 Cells Stained
Using the TUNEL Procedure
Cells were treated with 100 nM taxol for 3, 8,24,48, and 72 hours, stained using the
TUNEL procedure and photographed at 40 X magnification, as described in Materials
and Methods. Control cells containing no taxol were also cultured under the same
conditions and represented the 0 hours time point. Apoptotic MCF-7 cells were easily
identifiable as they were stained bright red. These data are representative of at least three
independent experiments.
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Figure 4.10. Representative Fluorescence Photomicrographs of MDA-MB-231 Cells
Stained Using the TUNEL Procedure
Cells were treated with 100 nM taxol for 3,8,24,48, and 72 hours, stained using the
TUNEL procedure and photographed at 40 X magnification, as described in Materials
and Methods. Control cells containing no taxol were also cultured under the same
conditions and represented the 0 hours time point. Apoptotic MDA-MB-231 cells were
easily identifiable as they were stained bright red. These data are representative of at least
three independent experiments.
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Figure 4.10. Representative Fluorescence Photomicrographs of MDA-MB-231 Cells
Stained Using the TUNEL Procedure
Cells were treated with 100 nM taxol for 3, 8,24,48, and 72 hours, stained using the
TUNEL procedure and photographed at 40 X magnification, as described in Materials
and Methods. Control cells containing no taxol were also cultured under the same
conditions and represented the 0 hours time point. Apoptotic MDA-MB-231 cells were
easily identifiable as they were stained bright red. These data are representative of at least
three independent experiments.
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Figure 4.10. Representative Fluorescence Photomicrographs of MDA-MB-231 Cell
Stained Using the TUNEL Procedure
Cells were treated with 100 nM taxol for 3, 8,24,48, and 72 hours, stained using the
TUNEL procedure and photographed at 40 X magnification, as described in Materials
and Methods. Control cells containing no taxol were also cultured under the same
conditions and represented the 0 hours time point. Apoptotic MDA-MB-231 cells were
easily identifiable as they were stained bright red. These data are representative of at least
three independent experiments.
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Figure 4.11. Percentage of Apoptotic MCF-7 Cells Determined Utilizing the TUNEL
Procedure
Cells were treated with 100 nM taxol for 3,8,24,48, and 72 hours, stained using the
TUNEL procedure and photographed at 40 X magnification, as described in Materials
and Methods. Control cells containing no taxol were also cultured under the same
conditions and represented the 0 hours time point. The number ofapoptotic cells out of
300 randomly selected cells was determined for each condition and the results were
expressed as mean +/- SD from at least three independent experiments. *P<0.05 and
**P<O.OOl are the statistical significance of the difference in the percentage of apoptotic
cells between control and treated cells.
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Figure 4.12. Percentage of Apoptotic MDA-MB-231 Cells Determined Utilizing the
TUNEL Procedure
Cells were treated with 100 nM taxol for 3, 8,24,48, and 72 hours, stained using the
TUNEL procedure and photographed at 40 X magnification, as described in Materials
and Methods. Control cells containing no taxol were also cultured under the same
conditions and represented the 0 hours time point. The number of apoptotic cells out of
300 randomly selected cells was determined for each condition and the results were
expressed as mean +/- SD from at least three independent experiments. ·P<0.05 and
..p<O.001 are the statistical significance of the difference in the percentage ofapoptotic
cells between control and treated cells.
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4.5 Apoptosis-Related Proteolytic Cleavage of PARP
Another prominent feature during apoptosis is the selective cleavage ofPARP by
caspase-3 and caspase-7 to generate 85- and 25-kDa fragments (Duriez, P .J., et ai., 1997).
To assess whether taxol induces PARP cleavage, protein lysate preparations from MCF-7
and MDA-MB-231 cells, which had been treated with 100 nM taxol for 3,8,24,48 and
72 hours were resolved on a 10% SDS-polyacrylamide gel. Subsequently, the protein was
transferred to Hybond™ ECLTM nitrocellulose membranes and immunoblots were
analyzed, as described in Materials and Methods. Control cells containing no taxol were
also cultured under the same conditions and represented the 0 hours time point. As shown
in Figure 4.13, PARP cleavage was detected, with the concomitant reduction of full size
(116 kDa) molecule and accumulation of the 85 kDa fragment, in MCF-7 cells after 24,
48 and 72 hours exposure to 100 nM taxol. In contrast, PARP was not cleaved in MDA-
MB-231 cells at any of the time points tested, as shown in Figure 4.14. Experiments were
repeated at least three times to ensure all results obtained were representative of the
conditions.
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Figure 4.13. Assessment ofPARP Cleavage in MCF-7 Cells
Total proteins (60 Ilg/lane) from MCF-7 cells treated with 100 nM taxol for 3, 8, 24, 48
and 72 hours were resolved on a 10% SDS-polyacrylarnide gel and transferred to
Hybond™ ECLTM nitrocellulose membranes. The protein levels were then assessed by
immunoblot analysis, as described in Materials and Methods. Control cells containing no
taxol were also cultured under the same conditions and represented the 0 hours time
point. The results shown are representative of at least three independent experiments.
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Figure 4.14. Assessment ofPARP Cleavage in MDA-MB-231 Cells
Total proteins (60 f.1g/lane) from MDA-MB-231 cells treated with 100 nM taxol for 3, 8,
24,48 and 72 hours were resolved on a 10% SDS-polyacrylamide gel and transferred to
Hybond™ ECLTM nitrocellulose membranes. The protein levels were then assessed by
immunoblot analysis, as described in Materials and Methods. Control cells containing no
taxol were also cultured under the same conditions and represented the 0 hours time
point. The results shown are representative of at least three independent experiments.
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4.6 Expression of p53 in MCF-7 and MDA-MB-231 Cells
The p53 tumor suppressor gene regulates a number of cellular responses to DNA
damage, including cell cycle arrest, some aspects ofDNA damage and apoptosis
(O'Connor, P. M., et aI., 1997; Hartwell, L.H., et aI., 1994; Zambetti, G.P., et aI., 1993).
To assess p53 expression, protein lysate preparations from MCF-7 and MDA-MB-231
cells, which had been treated with 100 nM taxol for 3,8,24,48 and 72 hours were
resolved on a 10% SDS-polyacrylamide gel. Subsequently, the protein was transferred to
Hybond™ ECLTM nitrocellulose membranes and immunoblots were analyzed, as
described in Materials and Methods. Control cells containing no taxol were also cultured
under the same conditions and represented the 0 hours time point. As shown in Figure
4.15, there was a statistically significant up-regulation in the expression ofp53 protein in
MCF-7 cells when exposed to 100 nM taxol for 72 hours, whereby the level ofp53 was
142% of the control. In contrast, there was a very statistically significant down-regulation
in the expression ofp53 protein in MDA-MB-231 cells when exposed to 100 nM taxol
for 72 hours. Specifically, the level ofp53 at this time point was 39% of the control, as
shown in Figure 4.16. Experiments were repeated at least three times to ensure that all
results obtained were representative of the conditions.
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Figure 4.15. Expression of p53 in MCF-7 Cells
Total proteins (20 flg/lane) from MCF-7 cells treated with 100 nM taxol for 3, 8, 24, 48
and 72 hours were resolved on a 10% SDS-polyacrylamide gel and transferred to
Hybond™ ECLTM nitrocellulose membranes. The protein levels were then assessed by
immunoblot analysis, as described in Materials and Methods. Control cells containing no
taxol were also cultured under the same conditions and represented the 0 hours time
point. Western blot and densitometric analysis are shown in the top and bottom panel,
respectively. Values represent the mean +/- SD of at least three independent experiments.
*P<0.05 and **p< 0.001 are the statistical significance of the difference in p53
expression between control and taxol-treated cells.
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Figure 4.16. Expression ofp53 in MDA-MB-231 Cells
Total proteins (5 Jlg/lane) from MDA-MB-231 cells treated with 100 nM taxol for 3,8,
24, 48 and 72 hours were resolved on a 10% SDS-polyacrylamide gel and transferred to
Hybond™ ECLTM nitrocellulose membranes. The protein levels were then assessed by
immunoblot analysis, as described in Materials and Methods. Control cells containing no
taxol were also cultured under the same conditions and represented the 0 hours time
point. Western blot and densitometric analysis are shown in the top and bottom panel,
respectively. Values represent the mean +/- SD of at least three independent experiments.
*P<0.05 and **p< 0.001 are the statistical significance of the difference in p53
expression between control and taxol-treated cells.
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4.7 Expression of Bcl-2 in MCF-7 and MDA-MB-231Cells
In recent years, it has been well established that Bcl-2 prevents most forms of
apoptotic cell death. To assess Bcl-2 expression, protein lysate preparations from MCF-7
and MDA-MB-231 cells, which had been treated with 100 nM taxol for 3,8,24,48 and
72 hours were resolved on a 10% SDS-polyacrylamide gel. Subsequently, the protein was
transferred to Hybond™ ECLTM nitrocellulose membranes and immunoblots were
analyzed, as described in Materials and Methods. Control cells containing no taxol were
also cultured under the same conditions and represented the 0 hours time point. As shown
in Figure 4.17, there was a statistically significant up-regulation in the expression ofBcl-
2 protein in MCF-7 cells when exposed to 100 nM taxol for 24 hours, whereby the level
ofBcl-2 was 173% of the control. In contrast, there was a statistically significant down-
regulation in the expression ofBcl-2 protein in MDA-MB-231 cells when exposed to 100
nM taxol for 72 hours. Specifically, the level ofBcl-2 at this time point was 34% ofthe
control, as shown in Figure 4.18. Experiments were repeated at least three times to ensure
that all results obtained were representative of the conditions.
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Figure 4.17. Expression of BcI-2 in MCF-7
Total proteins (60 /lg/lane) from MCF-7 cells treated with 100 nM taxol for 3, 8,24,48
and 72 hours were resolved on a 15% SDS-polyacrylamide gel and transferred to
Hybond™ ECLTM nitrocellulose membranes. The protein levels were then assessed by
immunoblot analysis, as described in Materials and Methods. Control cells containing no
taxol were also cultured under the same conditions and represented the 0 hours time
point. Western blot and densitometric analysis are shown in the top and bottom panel,
respectively. Values represent the mean +/- SD of at least three independent experiments.
*P<0.05 and **p< 0.001 are the statistical significance of the difference in Bcl-2
expression between control and taxol-treated cells.
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Figure 4.18. Expression of BcI-2 in MDA-MB-231 Cells
Total proteins (40 Ilg/lane) from MDA-MB-231 cells treated with 100 nM taxol for 3, 8,
24, 48 and 72 hours were resolved on a 15% SDS-polyacrylamide gel and transferred to
Hybond™ ECLTM nitrocellulose membranes. The protein levels were then assessed by
immunoblot analysis, as described in Materials and Methods. Control cells containing no
taxol were also cultured under the same conditions and represented the 0 hours time
point. Western blot and densitometric analysis are shown in the top and bottom panel,
respectively. Values represent the mean +/- SD of at least three independent experiments.
*P<0.05 and **p< 0.001 are the statistical significance of the difference in Bc1-2
expression between control and taxol-treated cells.
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4.8 Expression of Cytochrome c in MCF-7 and MDA-MB-231 Cells
In recent years, an increasing amount of interest has been directed toward the role
which cytochrome c has been documented to play in the apoptotic processes. Following
exposure to apoptotic stimuli, cytochrome c is rapidly released into the cytosol, an event
that is thought to be required for the completion of apoptosis (Kaufmann, SR., et al.,
2000). To assess cytochrome c expression, protein lysate preparations from MCF-7 and
MDA-MB-231 cells, which had been treated with 100 nM taxol for 3, 8, 24,48 and 72
hours were resolved on a 15% SDS-polyacrylamide gel. Subsequently, the protein was
transferred to Rybond™ ECLTM nitrocellulose membranes and immunoblots were
analyzed, as described in Materials and Methods. Control cells containing no taxol were
also cultured under the same conditions and represented the 0 hours time point. As shown
in Figure 4.19, there was no statistically significant change in the expression of
cytochrome c protein in MCF-7 cells when exposed to 100 nM taxol at any of the time
points examined. In contrast, there was a very statistically significant up-regulation in the
expression of cytochrome c in MDA-MB-231 cells when exposed to 100 nM taxol for 72
hours. Specifically, the level of cytochrome c at this time point was 173% of the control,
as shown in Figure 4.20. Experiments were repeated at least three times to ensure that all
results obtained were representative of the conditions.
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Figure 4.19. Expression of Cytochrome c in MCF-7 Cells
Total proteins (10 Ilgllane) from MCF-7 cells treated with 100 nM taxol for 3,8,24,48
and 72 hours were resolved on a 15% SDS-polyacrylamide gel and transferred to
Hybond™ ECLTM nitrocellulose membranes. The protein levels were then assessed by
immunoblot analysis, as described in Materials and Methods. Control cells containing no
taxol were also cultured under the same conditions and represented the 0 hours time
point. Western blot and densitometric analysis are shown in the top and bottom panel,
respectively. Values represent the mean +/- SD of at least three independent experiments.
*P<0.05 and **p< 0.001 are the statistical significance of the difference in cytochrome c
expression between control and taxol-treated cells.
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Figure 4.20. Expression of Cytochrome c in MDA-MB-231 Cells
Total proteins (10 Ilg/lane) from MCF-7 cells treated with 100 nM taxol for 3, 8, 24, 48
and 72 hours were resolved on a 15% SDS-polyacrylamide gel and transferred to
Hybond™ ECLTM nitrocellulose membranes. The protein levels were then assessed by
immunoblot analysis, as described in Materials and Methods. Control cells containing no
taxol were also cultured under the same conditions and represented the 0 hours time
point. Western blot and densitometric analysis are shown in the top and bottom panel,
respectively. Values represent the mean +/- SD of at least three independent experiments.
*P<0.05 and **p< 0.001 are the statistical significance of the difference in cytochrome c
expression between control and taxol-treated cells.
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CHAPTER 5: DISCUSSION AND CONCLUSIONS
Taxol is one of the most promising agents used for the clinical treatment of breast
cancer (Rowinsky, E.K., et a!., 1995; Holmes, F.A., et a!., 1991). It is known for its
unique ability to stabilize microtubules, thus preventing the completion of mitosis.
Studies have also shown that taxol exerts its cytotoxic effects via the induction of
apoptosis (Kaufmann, S.H., et al., 2000; Fan, W., 1999; McCloskey, D.E., et a!., 1996;
Bhalla, K., et a!., 1993). Specifically, research groups have reported that 100 nM taxol
can induce apoptosis in human breast cancer cell lines (Kottke, T.J., et a!., 2002; Kottke,
T. J., et a!., 1999; Samejima, K., et a!., 1999; McCloskey, D.E., et a!., 1996). As an
expansion of such previous work, taxol-induced apoptosis was assessed in MCF-7 and
MDA-MB-231 human breast adenocarcinoma cells. These cell lines were chosen in an
effort to highlight potential differences in the induction of apoptosis in response to
100 nM taxo!' MCF-7 cells express estrogen receptors and wild-type p53 gene and are
minimally invasive. On the other hand, MDA-MB-231 cells are estrogen receptor
negative, express mutant p53 gene and are highly invasive (Liu, Z., et a!., 1997; Elstner,
E., et a!., 1995).
To assess apoptosis, a number of techniques, designed to measure multiple aspects
of apoptosis, were examined. These included morphological assessment, TUNEL assay
and PARP cleavage. Morphological assessment by DIC microscopy and analysis of
chromatin condensation by Hoechst 33342 staining provided evidence oftaxol-induced
apoptosis in MCF-7 and MDA-MB-231 cells. Upon exposure to 100 nM taxol, both cell
lines exhibited typical morphological features associated with apoptotic cell death,
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including cell shrinkage, membrane blebbing, formation of apoptotic bodies and
chromatin condensation. These observations are consistent with a similar study ofMCF-7
cells, where 24 hours treatment with 100 nM taxol induced typical apoptotic-related
morphological features, such as chromatin condensation (Kottke, T.J., et aI., 2002).
Occurrence oftaxol-induced apoptosis ofMCF-7 and MDA-MB-231 cells was
further verified by DNA fragmentation. Because of the rarity of detecting DNA strand
breaks in MCF-7 cells by agarose gel electrophoresis, the TUNEL assay was employed.
Analysis ofDNA fragmentation revealed a time-dependent increase in DNA strand
breaks in taxol-treated MCF-7 and MDA-MB-231 cells. Because DNA fragmentation are
common features of apoptotic cells, this result provides further evidence oftaxol-induced
apoptosis in MCF-7 and MDA-MB-231 cells.
Another prominent feature during apoptosis is the selective cleavage ofPARP by
caspase-3 and caspase-7 to generate 85- and 25-kDa fragments. Using protein lysate
preparations, PARP cleavage was detected, with the concomitant reduction of full size
(116 kDa) molecule and accumulation of the 85-kDa fragment in MCF-7 cells after 24,
48 and 72 hours exposure to 100 nM taxo!' Interestingly, MCF-7 cells lack procaspase-3
polypeptide due to a 47-bp deletion within exon 3 of the procaspase-3 gene that alters the
reading frame of the message and results in an unstable truncated polypeptide (Janicke,
R.U., et aI., 1998). Hence, this result suggests that caspase-3 is not required for the
proteolytic cleavage ofPARP during taxol-induced apoptosis in MCF-7 cells. In contrast,
PARP cleavage was not detected in MDA-MB-231 cells at any of the time points tested,
an observation that is consistent with other literature reports (Blagosklonny, M.V., et ai.,
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2002). Because all of the previous parameters we have discussed are indicative oftaxol-
induced apoptosis in MDA-MB-231 cells, these data suggest that PARP itself is
dispensable in the apoptotic pathway. This observation is supported by recent studies that
have demonstrated that PARP-1- cells exhibit a normal apoptotic response to various
stimuli, including TNF-a and anti-Fas treatment (Leist, M., et al., 1997; Wang, Z.-Q., et
a!., 1997).
To further elucidate these findings, MCF-7 and MDA-MB-231 cells were
continuously exposed to taxol for different periods of time and the expression of various
apoptotic regulatory proteins were examined by western blot. Because the p53 tumor
suppressor gene is thought to mediate apoptosis, the expression of p53 in taxol-treated
MCF-7 and MDA-MB-231 cells was assessed. Upon exposure to 100 nM taxol, the
expression of p53 was significantly up-regulated in MCF-7 cells, suggesting that taxol-
induced apoptosis in this cell line occurs via a p53-dependent pathway. Conversely, taxol
decreased the expression of p53 in MDA-MB-231 cells following 72 hours treatment.
Interestingly, the p53 gene in MDA-MB-231 cells is deleted in one allele and mutated at
lys280 in exon 8 in the other allele, resulting in non-functional protein (Runnebaum, I.B.,
et al., 1994). Hence, this result suggests that taxol-induced apoptosis in MDA-MB-231
cells occurs via a p53-independent pathway. This observation is supported by studies that
have reported that taxol is capable of partly mediating apoptosis in a p53-independent
pathway, although the exact mechanism for this phenomenon is not clear (Fisher, D.E., et
a!., 1994). Perhaps, taxol can induce apoptosis in MDA-MB-231 cells, independently of
p53, through other mechanisms; at the nuclear level through its endonuclease activities, at
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the cell membrane through the activation of caspases, or at the mitochondria through the
release of cytochrome c. Further experiments would be required to further ascertain the
mechanism by which taxol induces apoptosis in MDA-MB-231 cells.
The expression level ofBcl-2 was also evaluated in MCF-7 and MDA-MB-231
cells treated with 100 nM taxo!' Unexpectedly, expression ofBcl-2 was significantly up-
regulated in MCF-7 cells following 24 hours exposure to taxo!' Because Bcl-2 is a potent
inhibitor of apoptosis, this result is not consistent with the previous results
(morphological assessment, chromatin condensation and TUNEL assay) suggesting the
induction of apoptosis in MCF-7 cells following 24 hours exposure to 100 nM taxo!' In
order to better understand this discrepancy, the constitutive levels and ratios ofBcl-2 and
other anti- and pro-apoptotic members of the Bcl-2 family should be ascertained, as they
are a determining factor in the control of apoptosis. However, it is possible that taxol-
induced apoptosis in MCF-7 cells may have occurred via a "Bcl-2 insensitive pathway",
such as that triggered by tumor necrosis factor or Fas ligand (Strasser, A., et aI., 2000).
Additionally, Bcl-2 may have other functions that are distinct from its ability to inhibit
apoptosis. Studies have suggested that overexpression ofBcl-2 may promote the exit of
cells from the cell cycle, as well as prevent quiescent Go-phase cells from re-entering the
cell cycle (Strasser, A., etal., 1997) Hence, the increased expression ofBcl-2 in MCF-7
cells following 24 hours exposure to 100 nM taxol may help prevent cells from re-
entering the cell cycle. In contrast, there was a significant down-regulation in the
expression ofBcl-2 protein in MDA-MB-231 cells exposed to 100 nM taxol for 72 hours.
Because Bcl-2 is a suppressor of apoptosis, this result suggests that the down-regulation
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ofBc1-2 might contribute to the induction of apoptosis in taxol-treated MDA-MB-231
cells. This finding is consistent with previous studies that have demonstrated that taxol-
induced cell death is associated with phosphorylation and subsequent degradation of the
Bc1-2 protein (Chadebech, P., et al., 1999; Kottke, T.J., et al., 1999; Srivastava, R.K., et
aI., 1999; Wang, W., et aI., 1999).
Studies have indicated that chemotherapeutic agent-induced apoptosis is often
associated with the release of cytochrome c from the mitochondria into the cytosol, which
is a critical event in the activation of caspase-9 and the induction of apoptosis
(Kaufmann, S.H., et aI., 2000). Hence, the expression level of cytochrome c was also
evaluated in MCF-7 and MDA-MB-231 cells treated with 100 nM taxo!' In MCF-7 cells,
there was no statistically significant change in the expression of cytochrome c when
exposed to 100 nM taxol at any of the time points examined. In contrast, there was a very
statistically significant up-regulation in the expression of cytochrome c in MDA-MB-231
cells when exposed to 100 nM taxol for 72 hours. Unfortunately, these results do not
provide any evidence suggesting the release of cytochrome c from the mitochondria. In
order to assess cytochrome c release, cell lysates should have undergone fractionation
and subsequent centrifugation in order to separate mitochondrial and cytosolic fractions
of cytochrome c and then western blot analysis should have been performed.
Furthermore, immunohistochemistry could have also been performed to determine the
localization of cytochrome c. Thus, these experiments would need to be performed in the
future to assess cytochrome c release.
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In conclusion, our project suggests that taxol induced apoptosis in MCF-7 and
MDA-MB-231 human breast adenocarcinoma cells. Treatment of these cells with 100
nM taxolled to chromatin condensation, DNA fragmentation, and apoptosis-associated
morphological changes after 3-24 hours exposure. Additionally, proteolytic cleavage of
PARP was detected in MCF-7 but not MDA-MB-231 cells. To further elucidate these
findings, the expression of certain apoptotic regulatory genes was also examined by
western blot analysis. In MCF-7 cells, levels ofBcl-2 and p53 increased after 24 hours
and 72 hours, respectively, whereas no significant change in levels of cytochrome c was
found. Conversely, in MDA-MB-231 cells, levels ofBcl-2 and p53 decreased after 72
hours, whereas cytochrome c levels increased after 72 hours. These data suggest that 100
nM taxol induces apoptosis in MCF-7 and MDA-MB-231 cells, probably via a p53-
dependent and independent pathway, respectively. Bcl-2 and cytochrome c, however, did
not play clear roles. The information from this project may increase understanding of
taxol-induced apoptosis and may aid the development of more effective taxol-based
chemotherapy regimens and improved clinical responses.
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